WO2010016527A1 - 癌の検出方法 - Google Patents
癌の検出方法 Download PDFInfo
- Publication number
- WO2010016527A1 WO2010016527A1 PCT/JP2009/063883 JP2009063883W WO2010016527A1 WO 2010016527 A1 WO2010016527 A1 WO 2010016527A1 JP 2009063883 W JP2009063883 W JP 2009063883W WO 2010016527 A1 WO2010016527 A1 WO 2010016527A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- seq
- antibody
- antigen
- polypeptide
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 331
- 201000011510 cancer Diseases 0.000 title claims abstract description 275
- 238000001514 detection method Methods 0.000 title claims abstract description 64
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 157
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 141
- 229920001184 polypeptide Polymers 0.000 claims abstract description 139
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 103
- 239000012634 fragment Substances 0.000 claims abstract description 71
- 230000014509 gene expression Effects 0.000 claims abstract description 55
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 53
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 53
- 239000002157 polynucleotide Substances 0.000 claims abstract description 53
- 238000006243 chemical reaction Methods 0.000 claims abstract description 48
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 34
- 230000009257 reactivity Effects 0.000 claims abstract description 12
- 101710072528 Caprin-1 Proteins 0.000 claims abstract description 11
- 102100029949 Caprin-1 Human genes 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 136
- 210000004027 cell Anatomy 0.000 claims description 105
- 108091007433 antigens Proteins 0.000 claims description 87
- 102000036639 antigens Human genes 0.000 claims description 86
- 239000000427 antigen Substances 0.000 claims description 80
- 210000001519 tissue Anatomy 0.000 claims description 56
- 206010006187 Breast cancer Diseases 0.000 claims description 54
- 208000026310 Breast neoplasm Diseases 0.000 claims description 52
- 210000002966 serum Anatomy 0.000 claims description 52
- 108020004999 messenger RNA Proteins 0.000 claims description 39
- 230000036961 partial effect Effects 0.000 claims description 38
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 25
- 238000003018 immunoassay Methods 0.000 claims description 25
- 230000036210 malignancy Effects 0.000 claims description 23
- 230000003211 malignant effect Effects 0.000 claims description 23
- 208000009956 adenocarcinoma Diseases 0.000 claims description 21
- 206010025323 Lymphomas Diseases 0.000 claims description 18
- 125000000539 amino acid group Chemical group 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 206010039491 Sarcoma Diseases 0.000 claims description 13
- 238000001727 in vivo Methods 0.000 claims description 12
- 201000001441 melanoma Diseases 0.000 claims description 11
- 238000005259 measurement Methods 0.000 claims description 10
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 9
- 201000006512 mast cell neoplasm Diseases 0.000 claims description 9
- 208000006971 mastocytoma Diseases 0.000 claims description 9
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 8
- 201000009030 Carcinoma Diseases 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 8
- 201000010260 leiomyoma Diseases 0.000 claims description 8
- 210000004072 lung Anatomy 0.000 claims description 7
- 208000007369 Malignant Mixed Tumor Diseases 0.000 claims description 6
- 208000010932 epithelial neoplasm Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 206010003445 Ascites Diseases 0.000 claims description 5
- 208000006402 Ductal Carcinoma Diseases 0.000 claims description 5
- 208000002151 Pleural effusion Diseases 0.000 claims description 5
- 210000003128 head Anatomy 0.000 claims description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 5
- 208000021810 malignant mixed neoplasm Diseases 0.000 claims description 5
- 208000028591 pheochromocytoma Diseases 0.000 claims description 5
- 210000001732 sebaceous gland Anatomy 0.000 claims description 5
- 210000004291 uterus Anatomy 0.000 claims description 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 206010011732 Cyst Diseases 0.000 claims description 4
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 4
- 208000005234 Granulosa Cell Tumor Diseases 0.000 claims description 4
- 208000002291 Histiocytic Sarcoma Diseases 0.000 claims description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 4
- 208000003274 Sertoli cell tumor Diseases 0.000 claims description 4
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 210000003503 anal sac Anatomy 0.000 claims description 4
- 201000007436 apocrine adenocarcinoma Diseases 0.000 claims description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 208000031513 cyst Diseases 0.000 claims description 4
- 201000004528 gastrointestinal lymphoma Diseases 0.000 claims description 4
- 238000007912 intraperitoneal administration Methods 0.000 claims description 4
- 201000003330 leiomyoma cutis Diseases 0.000 claims description 4
- 201000008968 osteosarcoma Diseases 0.000 claims description 4
- 201000005218 sebaceous adenoma Diseases 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 208000006274 Brain Stem Neoplasms Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 claims description 3
- 230000001919 adrenal effect Effects 0.000 claims description 3
- 201000008275 breast carcinoma Diseases 0.000 claims description 3
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 claims description 3
- 201000003911 head and neck carcinoma Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 210000003739 neck Anatomy 0.000 claims description 3
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 claims description 3
- 208000012991 uterine carcinoma Diseases 0.000 claims description 3
- 230000001720 vestibular Effects 0.000 claims description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 2
- 210000004907 gland Anatomy 0.000 claims description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 2
- 201000005296 lung carcinoma Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 230000001900 immune effect Effects 0.000 claims 1
- 201000010198 papillary carcinoma Diseases 0.000 claims 1
- 201000010965 sweat gland carcinoma Diseases 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 127
- 241000282472 Canis lupus familiaris Species 0.000 description 82
- 102000004169 proteins and genes Human genes 0.000 description 69
- 235000018102 proteins Nutrition 0.000 description 66
- 239000000243 solution Substances 0.000 description 58
- 239000000523 sample Substances 0.000 description 51
- 238000003745 diagnosis Methods 0.000 description 50
- 241000282465 Canis Species 0.000 description 43
- 238000002835 absorbance Methods 0.000 description 32
- 239000002953 phosphate buffered saline Substances 0.000 description 28
- 206010027476 Metastases Diseases 0.000 description 24
- 230000009401 metastasis Effects 0.000 description 24
- 102000039446 nucleic acids Human genes 0.000 description 23
- 108020004707 nucleic acids Proteins 0.000 description 23
- 150000007523 nucleic acids Chemical class 0.000 description 23
- 241000588724 Escherichia coli Species 0.000 description 22
- 239000002299 complementary DNA Substances 0.000 description 22
- 238000001356 surgical procedure Methods 0.000 description 22
- 238000005406 washing Methods 0.000 description 22
- 238000012360 testing method Methods 0.000 description 21
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 19
- 101000793727 Homo sapiens Caprin-1 Proteins 0.000 description 18
- 230000000903 blocking effect Effects 0.000 description 18
- 102000052098 human CAPRIN1 Human genes 0.000 description 18
- 241000282326 Felis catus Species 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- 238000011282 treatment Methods 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 16
- 241000124008 Mammalia Species 0.000 description 15
- 210000004408 hybridoma Anatomy 0.000 description 15
- 239000013604 expression vector Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 11
- 238000003199 nucleic acid amplification method Methods 0.000 description 11
- 238000003757 reverse transcription PCR Methods 0.000 description 11
- 239000007790 solid phase Substances 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 241000282412 Homo Species 0.000 description 10
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 10
- 229940098773 bovine serum albumin Drugs 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 239000012091 fetal bovine serum Substances 0.000 description 10
- 210000001550 testis Anatomy 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 239000008363 phosphate buffer Substances 0.000 description 9
- 108091008146 restriction endonucleases Proteins 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 8
- 238000007796 conventional method Methods 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 238000010827 pathological analysis Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 241000283707 Capra Species 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 108010052285 Membrane Proteins Proteins 0.000 description 6
- 102000018697 Membrane Proteins Human genes 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 6
- 210000001165 lymph node Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 108020004635 Complementary DNA Proteins 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- 238000000137 annealing Methods 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 229940041181 antineoplastic drug Drugs 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 210000001508 eye Anatomy 0.000 description 5
- 238000011532 immunohistochemical staining Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 239000012460 protein solution Substances 0.000 description 5
- 239000000439 tumor marker Substances 0.000 description 5
- 239000008096 xylene Substances 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 4
- 102000003992 Peroxidases Human genes 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- -1 aromatic amino acids Chemical class 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000004040 coloring Methods 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 210000005075 mammary gland Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 230000002980 postoperative effect Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 210000004989 spleen cell Anatomy 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 230000001131 transforming effect Effects 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 101000918303 Bos taurus Exostosin-2 Proteins 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 208000000779 Gingival Neoplasms Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 201000007295 breast benign neoplasm Diseases 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000013599 cloning vector Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 235000013861 fat-free Nutrition 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000003100 immobilizing effect Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 3
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011897 real-time detection Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 201000008759 sweat gland cancer Diseases 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 2
- 206010055113 Breast cancer metastatic Diseases 0.000 description 2
- 101100494773 Caenorhabditis elegans ctl-2 gene Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102100029727 Enteropeptidase Human genes 0.000 description 2
- 108010013369 Enteropeptidase Proteins 0.000 description 2
- 101100112369 Fasciola hepatica Cat-1 gene Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 101150112014 Gapdh gene Proteins 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 208000006050 Hemangiopericytoma Diseases 0.000 description 2
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 101100005271 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cat-1 gene Proteins 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 201000008274 breast adenocarcinoma Diseases 0.000 description 2
- 238000010805 cDNA synthesis kit Methods 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- XFIOKOXROGCUQX-UHFFFAOYSA-N chloroform;guanidine;phenol Chemical compound NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 XFIOKOXROGCUQX-UHFFFAOYSA-N 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 239000006167 equilibration buffer Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 238000002350 laparotomy Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000012120 mounting media Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 238000002205 phenol-chloroform extraction Methods 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000012521 purified sample Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 208000018964 sebaceous gland cancer Diseases 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 101150116295 CAT2 gene Proteins 0.000 description 1
- 101100326920 Caenorhabditis elegans ctl-1 gene Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 101100348617 Candida albicans (strain SC5314 / ATCC MYA-2876) NIK1 gene Proteins 0.000 description 1
- 241000701114 Canine adenovirus 2 Species 0.000 description 1
- 241000711506 Canine coronavirus Species 0.000 description 1
- 241000712083 Canine morbillivirus Species 0.000 description 1
- 241000701931 Canine parvovirus Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000010772 Dog disease Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- UFNSPPFJOHNXRE-AUTRQRHGSA-N Gln-Gln-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O UFNSPPFJOHNXRE-AUTRQRHGSA-N 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- 101100326758 Homo sapiens CAPRIN1 gene Proteins 0.000 description 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 1
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- NHXXGBXJTLRGJI-GUBZILKMSA-N Met-Pro-Ser Chemical compound [H]N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O NHXXGBXJTLRGJI-GUBZILKMSA-N 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 101100005280 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cat-3 gene Proteins 0.000 description 1
- 101100126846 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) katG gene Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 208000008071 Parvoviridae Infections Diseases 0.000 description 1
- 206010057343 Parvovirus infection Diseases 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 102100038358 Prostate-specific antigen Human genes 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 101100007329 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS1 gene Proteins 0.000 description 1
- 241000235343 Saccharomycetales Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 241000981595 Zoysia japonica Species 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 201000010425 adrenal medulla cancer Diseases 0.000 description 1
- 208000024727 adrenal medulla neoplasm Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 208000010717 cat disease Diseases 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 210000001703 glandular epithelial cell Anatomy 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 238000012333 histopathological diagnosis Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 230000006122 isoprenylation Effects 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 208000029691 metastatic malignant neoplasm in the lymph nodes Diseases 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000010882 preoperative diagnosis Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000009790 vascular invasion Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
Definitions
- the present invention relates to a method for detecting cancer using CAPRIN-1 as a tumor marker.
- Cancer is a disease that occupies the top cause of all deaths, and currently the main treatment is coping therapy, which is a combination of radiation therapy and chemotherapy, mainly surgery. Until now, the development of medical technology has made cancer more likely to be cured if detected early. Therefore, there is a need for a method for detecting cancer that can be easily examined using serum, urine, etc. without the physical and economic burden of cancer patients.
- Tumor products refer to tumor-related antigens, enzymes, specific proteins, metabolites, oncogenes, oncogene products, tumor suppressor genes, and the like, including carcinoembryonic antigen CEA, glycoproteins CA19-9, CA125, Prostate-specific antigen PSA, calcitonin, a peptide hormone produced in the thyroid gland, and the like have been utilized for cancer diagnosis as tumor markers in some cancers.
- carcinoembryonic antigen CEA carcinoembryonic antigen
- glycoproteins CA19-9, CA125 glycoproteins CA125
- Prostate-specific antigen PSA Prostate-specific antigen PSA
- calcitonin a peptide hormone produced in the thyroid gland
- a cancer diagnosed in an invisible part can be diagnosed, it is useful for early detection of a cancer that is difficult to notice, such as in the abdominal cavity.
- a cancer that cannot be found by ultrasonic examination, CT (computer tomography) or MRI (nuclear magnetic resonance imaging) can be found.
- the degree of cancer progression is classified based on the extent of the tumor at the primary site and the presence or absence of metastasis to regional lymph nodes or distant organs.
- a stage called a stage is classified into five stages, and progresses as the number increases. Strictly, the definition differs depending on the organ.
- stage 0 is a cancer that remains in the epithelium
- stage IV is a cancer that causes distant metastasis.
- treatment decisions include prostate cancer, which has a very low grade of malignancy and is rarely progressing and does not require treatment, while metastasis to bone or other causes of death causes the patient to die.
- Treatments such as hormonal therapy and excision surgery have side effects, so it is necessary to determine and determine the appropriate treatment.
- the selection of an anticancer agent is appropriate and the timing of finishing the administration of the anticancer agent, the physical and economic burden on the patient can be reduced. Therefore, it is important that the degree of progression can be diagnosed.
- cancer cells One characteristic of cancer cells is their ability to rejuvenate or dedifferentiate. Except for some cancers, cancer cells that are poorly differentiated or undifferentiated and have a lower degree of differentiation have a faster growth after metastasis and a poorer prognosis. Such cancer is said to have high malignancy. Conversely, highly differentiated cancer cells, that is, those with a high degree of cell differentiation, retain the structure and functional properties of the organ, and can be said to be relatively low in malignancy. When the malignancy of such cancer is known, even if the tumor is small, if the malignancy is high, it is possible to secure a large margin at the time of tumor removal, or to observe the area with attention to a wide range of surrounding tissues.
- a postoperative diagnosis including recurrence and metastasis can be made, it is possible to diagnose whether the tumor has been completely removed by surgery. If the excision is not complete, recurrence is likely to occur, which can be used as a basis for careful follow-up at shorter intervals and, in some cases, early reoperation. In addition, it is highly possible that it can be detected early if it recurs. If remote metastasis has occurred, discovery tends to be delayed, but if metastasis diagnosis is possible, it will be a criterion for expanding the examination range beyond the excision site and its surroundings.
- Cytoplasma-and promotion-associated protein 1 (CAPRIN-1) is expressed when quiescent normal cells are activated or undergo cell division, and also forms RNA and intracellular stress granules within the cell to transport mRNA It is an intracellular protein known to be involved in the control of translation.
- CAPRIN-1 Cytoplasma-and promotion-associated protein 1
- examples include GPI-anchored membrane protein 1 and Membrane component surface marker protein 1 (M11S1), and this protein is a cell membrane protein. There is a name as if it was known.
- M11S1 Membrane component surface marker protein
- the CAPRIN-1 gene sequence is incorrect, and the CAPRIN-1 gene sequence currently registered in GenBank et al. Loses 80 amino acids from the C-terminal due to a frame shift due to a single base deletion.
- the resulting artifact (74 amino acids) is the GPI-binding portion in the previous report, and there is also a gene sequence error on the 5 ′ side, and it has been proved that 53 amino acids are deleted from the N-terminal (Non-patent literature) 10). It has also been reported that the protein encoded by the gene sequence of CAPRIN-1 currently registered in GenBank et al. Is not a cell membrane protein (Non-patent Document 10).
- Patent Documents 1 and 2 include the name M11S1, and CAPRIN-1 is one of the cell membrane proteins and is a target for cancer treatment and the like. (It is not described in the examples at all).
- Non-Patent Document 10 from the time of the filing of Patent Documents 1 and 2, until now, it has become common knowledge that CAPRIN-1 is not expressed on the cell surface. It is clear that the contents of Patent Documents 1 and 2 based only on erroneous information that they are cell membrane proteins should not be understood as technical common knowledge for those skilled in the art.
- CAPRIN-1 is highly expressed in cancer cells such as breast cancer compared to normal cells.
- An object of the present invention is to provide a cancer detection means useful for cancer diagnosis.
- the present inventors have obtained a cDNA encoding a protein that binds to an antibody present in serum derived from a cancer-bearing organism by the SEREX method using a dog testis-derived cDNA library and the serum of a cancer-bearing dog. Obtained, and based on the cDNA, canine CAPRIN-1 having the amino acid sequence shown in SEQ ID NOs: 6, 8, 10, 12, and 14 was prepared. In addition, based on the human homologous gene of the obtained gene, human CAPRIN-1 having the amino acid sequences shown in SEQ ID NOs: 2 and 4 was prepared.
- the genes encoding these proteins are specifically expressed in canine and human testis and malignant cancer cells (see Example 1 described later), and a set prepared based on the amino acid sequences of these proteins It has been found that the replacement polypeptide specifically reacts only with serum in the cancer-bearing organism, and further, using the antibody prepared using the recombinant polypeptide, the CAPRIN-1 is specifically produced from the cancer-bearing organism.
- the present invention was completed.
- the present invention provides a method for detecting cancer, which is a method performed on a sample separated from a living body, and includes measuring the expression of CAPRIN-1.
- the present invention also provides a cancer detection reagent comprising a polypeptide that undergoes an antigen-antibody reaction with an antibody induced in vivo against CAPRIN-1.
- the present invention provides a cancer detection reagent comprising an antibody or an antigen-binding fragment thereof that reacts with CAPRIN-1 in an antigen-antibody reaction.
- the present invention relates to 15 bases or more, preferably 20 to 25 bases or more, more preferably 30 bases or more in the base sequences shown in SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13 etc.
- a cancer detection reagent comprising a polynucleotide that specifically hybridizes with a partial sequence of
- the present invention has the following features.
- a method for detecting cancer comprising measuring the expression of a polypeptide comprising:
- the polypeptide to be measured is a CAPRIN-1 protein having any amino acid sequence represented by an even sequence number among SEQ ID NOs: 2 to 30, or 85% or more of sequence identity to the CAPRIN-1 protein
- the measurement of the expression of the polypeptide is performed by immunoassay of the antibody induced in the living body against the polypeptide to be measured, which can be contained in the sample (1) to (6) The method in any one of.
- the living body is a dog, and the polynucleotide is 15 bases or more, preferably 20 to 25 bases or more, more preferably 30 bases or more in the base sequence shown in SEQ ID NO: 5, 7, 9, 11 or 13.
- the living body is human, and the polynucleotide is specific to a partial sequence of 15 bases or more, preferably 20 to 25 bases or more, more preferably 30 bases or more in the base sequence shown in SEQ ID NO: 1 or 3.
- the cancer is brain tumor, head, neck, lung, uterus, or esophageal squamous cell carcinoma, melanoma, lung or uterine adenocarcinoma, renal cancer, malignant mixed tumor, hepatocellular carcinoma, basal cell carcinoma, sputum cell Tumorous gingival tumor, oral mass, perianal adenocarcinoma, anal cyst mass, anal sac apocrine adenocarcinoma, Sertoli cell tumor, vaginal vestibular cancer, sebaceous gland cancer, sebaceous gland epithelioma, sebaceous gland adenoma, sweat gland cancer, intranasal adenocarcinoma Nasal adenocarcinoma, thyroid cancer, colon cancer, bronchial adenocarcinoma, adenocarcinoma, ductal cancer, breast cancer, complex breast cancer, malignant mixed breast tumor, intraductal papillary adenocarcinoma,
- a cancer detection reagent comprising a polypeptide having:
- a cancer detection reagent comprising an antibody or antigen-binding fragment thereof that reacts with an antigen with an antibody.
- a cancer detection reagent comprising a polynucleotide that hybridizes spontaneously.
- the present invention provides a novel method for detecting cancer.
- a recombinant polypeptide prepared based on the amino acid sequence of CAPRIN-1 (or Caprin-1) is an antibody that specifically exists in the serum of cancer patients React with. Therefore, if the antibody in a sample is measured by the method of the present invention, cancer in vivo can be detected. In vivo cancer can also be detected by measuring CAPRIN-1 itself. According to the method of the present invention, a cancer of a small size that cannot be seen by the eye or a cancer in the deep part of the body can be detected, so that it is useful for early detection of cancer in health examinations and the like.
- the method of this invention is utilized for the follow-up of the patient after cancer treatment, the cancer which recurred can also be detected at an early stage. Furthermore, according to the method of the present invention, it is possible to diagnose the degree of cancer progression such as tumor growth, infiltration into surrounding tissues, and cancer metastasis to lymph nodes and distant organs. Moreover, since the abundance of the antibody in serum is higher in cancer patients with high malignancy than in cancer patients with low malignancy, the method of the present invention can also diagnose the malignancy of cancer. In addition, as described in the Examples below, mRNA encoding CAPRIN-1 is specifically highly expressed in testis and cancer cells. Therefore, cancer can also be detected by measuring the mRNA.
- the expression of CAPRIN-1 is measured using a sample separated from a living body.
- Methods for measuring the expression of CAPRIN-1 include immunoassay of antibodies against CAPRIN-1 contained in a sample (first method), and immunoassay of CAPRIN-1 itself contained in a sample (first method). 2) and a method of measuring mRNA encoding CAPRIN-1 contained in a sample (third method).
- the expression of CAPRIN-1 may be measured by any of these methods.
- the term “measurement” includes detection, qualitative, quantitative, and semi-quantitative.
- the amino acid sequence shown in SEQ ID NO: 6, 8, 10, 12 or 14 is the amino acid sequence of canine CAPRIN-1.
- Canine CAPRIN-1 having the amino acid sequence is a polypeptide that binds to an antibody specifically present in serum derived from a cancer-bearing dog by the SEREX method using a dog testis-derived cDNA library and the serum of the cancer-bearing dog. Have been identified (see Example 1). That is, an antibody against CAPRIN-1 having the amino acid sequence shown in SEQ ID NO: 6, 8, 10, 12, or 14 is specifically induced in cancer-bearing dogs.
- canine cancer can be detected by measuring the above-mentioned antibody against CAPRIN-1 having the amino acid sequence shown in SEQ ID NO: 6, 8, 10, 12, or 14 by the first method (Example 3 and 4).
- canine cancer can also be detected by measuring CAPRIN-1 itself of SEQ ID NO: 6, 8, 10, 12 or 14 as an antigen by the second method (see Examples 5 and 6).
- CAPRIN-1 itself of SEQ ID NO: 6, 8, 10, 12 or 14 as an antigen by the second method.
- mRNA encoding CAPRIN-1 is significantly highly expressed in testis and cancer cells (see Example 1), it is also possible to measure the mRNA by measuring the mRNA. Cancer can be detected.
- a polypeptide having the amino acid sequence represented by SEQ ID NO: 2 means 709 amino acids having the amino acid sequence of Met Pro Ser Ala, extended, Gln Gln Val Asn represented by SEQ ID NO: 2.
- a residue size polypeptide is meant.
- polypeptide having the amino acid sequence represented by SEQ ID NO: 2 may be abbreviated as “polypeptide of SEQ ID NO: 2”. The same applies to the expression “having a base sequence”. In this case, the term “comprising” may be replaced by the expression “consisting of”.
- polypeptide refers to a molecule formed by peptide bonding of a plurality of amino acids, and not only a polypeptide molecule having a large number of amino acids but also a low number of amino acids. Molecular weight molecules (oligopeptides) and full-length proteins are also included. In the present invention, CAPRIN-1 full-length protein having an amino acid sequence represented by an even SEQ ID NO.
- CAPRIN-1 not only canine CAPRIN-1 of SEQ ID NO: 6, 8, 10, 12 or 14 but also other mammalian CAPRIN-1 (hereinafter referred to as “homologous factor” (or “homologue for canine CAPRIN-1).
- CAPRIIN-1 is not limited to dogs, but includes CAPRIN-1 derived from other mammals).
- mRNA encoding human CAPRIN-1 is significantly higher in human testis and cancer cells, as canine CAPRIN-1 of SEQ ID NO: 6, 8, 10, 12 or 14. It is expressed and no antibody against the human CAPRIN-1 is detected in a healthy human body.
- CAPRIN-1 other than dogs to be measured by the method of the present invention include, but are not limited to, human CAPRIN-1, cat CAPRIN-1, and the like.
- the base sequence encoding human CAPRIN-1 and its amino acid sequence are as shown in SEQ ID NOs: 1, 3 and 2, 4 of the sequence listing, respectively.
- the sequence identity with canine CAPRIN-1 is the base sequence. 94%, amino acid sequence 98%.
- CAPRIN-1 for measuring expression in the method of the present invention is not particularly limited, but preferably has an amino acid sequence of canine CAPRIN-1 shown in SEQ ID NO: 6, 8, 10, 12, or 14 and more preferably 85% or more. Preferably it has 95% or more sequence identity.
- measurement of the antibody that may be present in the sample can be easily performed by immunoassay using an antigenic substance that reacts with the antibody in an antigen-antibody reaction.
- the immunoassay method itself is a well-known conventional method as described in detail below.
- an antigen substance for immunoassay for example, canine CAPRIN-1 of SEQ ID NO: 6, 8, 10, 12, or 14 that has induced the antibody in cancer-bearing dogs can be used.
- antibodies are cross-reactive, and even molecules other than the antigenic substance that actually became the immunogen can be used as immunogens if a structure similar to the epitope of the immunogen exists on the molecule. It can bind to the antibody induced against it by an antigen-antibody reaction.
- the sequence identity of the amino acid sequence is high and the epitope structure is often similar.
- the canine CAPRIN-1 of SEQ ID NO: 6, 8, 10, 12 or 14 is an antibody-antigen-antibody reaction induced by the canine CAPRIN-1 in a cancer-bearing dog.
- the antibody induced against the cat CAPRIN-1 in the cancer-bearing cat reacts with an antigen-antibody, and human CAPRIN-1 and the above-mentioned antibody induced in the cancer-bearing dog body and the cancer-bearing cat body. Antigen-antibody reaction. Therefore, in the first method of the present invention, CAPRIN-1 derived from any mammal can be used as an antigen for immunoassay.
- an antibody produced in vivo against an antigenic substance such as a protein is a polyclonal antibody that is a mixture of a plurality of types of antibodies.
- the antibody found by the present inventors specifically in serum derived from a cancer-bearing organism and specifically binding to a recombinant CAPRIN-1 protein by an antigen-antibody reaction is also a polyclonal antibody.
- the term “polyclonal antibody” refers to an antibody that is present in serum derived from a living body containing an antigen substance in the body and that is induced in the living body with respect to the antigen substance.
- the polypeptides of SEQ ID NO: 6 and SEQ ID NO: 8 canine CAPRIN-1) and SEQ ID NO: 2 (human CAPRIN-1 ) And the reactivity of these polypeptides with the antibody in serum derived from a cancer-bearing organism has been confirmed.
- the antibody since the antibody is a polyclonal antibody, it naturally binds if it is a polypeptide consisting of the homologous factor of SEQ ID NO: 6, 8 or 2, and even a fragment of the polypeptide is contained in the polyclonal antibody.
- the polypeptide used as an immunoassay antigen in the first method of the present invention is not limited to a polypeptide consisting of the full-length region of CAPRIN-1 (eg, SEQ ID NO: 6, 8, or 2).
- a polypeptide fragment consisting of 7 or more, preferably 8 or more, 9 or more, or 10 or more consecutive amino acids in the amino acid sequence of the polypeptide, wherein the antibody fragment reacts with a polyclonal antibody against CAPRIN-1 Peptides (hereinafter also referred to as “specifically reactive partial polypeptides” for convenience) are also included.
- a polypeptide having about 7 amino acid residues or more exhibits antigenicity.
- the number of amino acid residues is too small, there is a high possibility of cross-reaction with antibodies against proteins other than CAPRIN-1 present in the sample.
- the number of amino acid residues of the polypeptide fragment is preferably 30 or more, or 50 or more, more preferably 100 or more, or 150 or more, more preferably 300 or more, more preferably It is desirable that the number be 600 or more, and it may be 1000 or more and 1500 or more.
- polypeptide used as the antigen is an even-numbered polypeptide of SEQ ID NOs: 2 to 30 or a fragment thereof.
- nucleotide sequences of the polynucleotides encoding the proteins consisting of the amino acid sequences of even numbers among SEQ ID NOs: 2 to 30 are respectively SEQ ID NOs: 1 to It is shown by the odd number sequence number (namely, sequence number 1,3,5..27,29) among 29.
- a protein antigen has almost the same antigenicity as the original protein even when a few amino acid residues in the amino acid sequence of the protein are replaced, deleted, added, or inserted. It is well known to those skilled in the art that Accordingly, a polypeptide having a sequence in which a few (preferably one or several) amino acid residues in CAPRIN-1 are substituted, deleted and / or inserted, 80% or more, 85% or more, preferably 90% or more, more preferably 95% or more, and still more preferably 98% or more, and a polyclonal antibody against CAPRIN-1 and an antigen-antibody reaction A polypeptide that binds more specifically (hereinafter sometimes referred to as “specific reactive modified polypeptide” for convenience) can also be used for detection of cancer in the same manner as the above-described polypeptide.
- the specific reactive modified polypeptide has an amino acid sequence in which one or several amino acid residues are substituted, deleted, added, and / or inserted in the amino acid sequence of CAPRIN-1.
- the “several” in the present specification represents an integer of 2 to 10, preferably an integer of 2 to 6, and more preferably an integer of 2 to 4.
- sequence identity of amino acid sequences refers to the number of amino acid residues that are aligned by aligning both amino acid sequences so that the amino acid residues of the two amino acid sequences to be compared match as much as possible. Is divided by the total number of amino acid residues and expressed as a percentage. In the above alignment, a gap is appropriately inserted in one or both of the two sequences to be compared as necessary.
- alignment of sequences can be performed using a known program such as BLAST, FASTA, CLUSTAL W, etc. (Karlin and Altschul, Proc. Natl. Acad. Sci. USA, 87: 2264-2268, 1993; Altschul et al., Nucleic Acids Res., 25: 3389-3402, 1997).
- the 20 amino acids constituting the natural protein are neutral amino acids having low polarity side chains (Gly, Ile, Val, Leu, Ala, Met, Pro), neutral amino acids having hydrophilic side chains (Asn). , Gln, Thr, Ser, Tyr, Cys, acidic amino acids (Asp, Glu), basic amino acids (Arg, Lys, His), aromatic amino acids (Phe, Tyr, Trp, His)
- Asp acidic amino acids
- Arg Lys, His
- aromatic amino acids Phe, Tyr, Trp, His
- the above-described variant may have a non-conservative substitution as long as it imparts immunity-inducing activity equivalent to or almost equivalent to that of the unmodified product.
- a polypeptide comprising the above-mentioned polypeptide used in the present invention as a partial sequence that is, a polypeptide used in the present invention having one or both ends added with another (poly) peptide), and a polyclonal antibody against CAPRIN-1;
- a polypeptide that specifically binds by an antigen-antibody reaction hereinafter, sometimes referred to as “specific reactive addition polypeptide” for convenience
- the polypeptide used in the present invention can be synthesized according to chemical synthesis methods such as Fmoc method (fluorenylmethyloxycarbonyl method) and tBoc method (t-butyloxycarbonyl method) (edited by the Japanese Biochemical Society). Biochemistry Experiment Course 1, Protein Chemistry IV, Chemical Modification and Peptide Synthesis, Tokyo Chemical Doujin (Japan), 1981). Moreover, it can also synthesize
- a cDNA of the gene is prepared by RT-PCR from RNA extracted from a tissue expressing a gene encoding human CAPRIN-1 of SEQ ID NO: 2 or a homologous factor thereof, and the full length of the cDNA or a desired one is obtained.
- the part can be incorporated into an expression vector and introduced into a host cell to obtain the desired polypeptide.
- nucleotide sequences of cDNAs encoding canine CAPRIN-1 of SEQ ID NOs: 6, 8, 10, 12 and 14 are shown in SEQ ID NOs: 5, 7, 9, 11 and 13, respectively, and their human homologous factors SEQ ID NOs: 2 and 4 Since the nucleotide sequences of cDNAs encoding human CAPRIN-1 are shown in SEQ ID NOs: 1 and 3, respectively, primers used for RT-PCR can be easily designed with reference to these nucleotide sequences.
- the gene encoding CAPRIN-1 of mammals other than humans can be amplified with primers designed with reference to the nucleotide sequence of the odd sequence number among SEQ ID NOs: 1 to 29.
- a cDNA encoding CAPRIN-1 can also be easily prepared by the same method as described above. Extraction of RNA, RT-PCR, integration of cDNA into a vector, and introduction of a vector into a host cell can be performed by well-known methods, for example, as described below. Further, vectors and host cells to be used are well known, and various types are commercially available.
- the host cell may be any cell that can express the polypeptide.
- prokaryotic cells include Escherichia coli
- examples of eukaryotic cells include monkey kidney cells COS1 and Chinese hamster ovary cells.
- Examples include mammalian cultured cells such as CHO, human fetal kidney cell line HEK293, mouse fetal skin cell line NIH3T3, budding yeast, fission yeast, silkworm cells, and Xenopus egg cells.
- the expression vector When a prokaryotic cell is used as a host cell, the expression vector includes an origin, promoter, ribosome binding site, multicloning site, terminator, drug resistance gene, auxotrophic complementary gene, etc. that can be replicated in the prokaryotic cell. Is used. Examples of the expression vector for E. coli include pUC system, pBluescript II, pET expression system, pGEX expression system and the like. When the DNA encoding the above polypeptide is incorporated into such an expression vector, a prokaryotic host cell is transformed with the vector, and the resulting transformant is cultured, the polypeptide encoded by the DNA is prokaryotic. It can be expressed in a host cell.
- the polypeptide can also be expressed as a fusion protein with another protein.
- the DNA encoding the polypeptide can be obtained, for example, by preparing cDNA by RT-PCR as described above, or can be synthesized by a conventional method using a commercially available nucleic acid synthesizer as described later. it can.
- the nucleotide sequences of cDNAs of genes encoding CAPRIN-1 of SEQ ID NOs: 2 and 4 are shown in SEQ ID NOS: 1 and 3, respectively.
- an expression vector for a eukaryotic cell having a promoter, a splicing region, a poly (A) addition site and the like is used as an expression vector.
- expression vectors include pKA1, pCDM8, pSVK3, pMSG, pSVL, pBK-CMV, pBK-RSV, EBV vector, pRS, pcDNA3, pYES2, and the like.
- the DNA encoding the polypeptide used in the present invention is incorporated into such an expression vector, and after transforming a eukaryotic host cell with the vector, the obtained transformant is cultured.
- Polypeptides encoded by the DNA can be expressed in eukaryotic host cells.
- pIND / V5-His, pFLAG-CMV-2, pEGFP-N1, pEGFP-C1, etc. are used as an expression vector, a His tag (eg (His) 6 to (His) 10 ), FLAG tag, myc tag
- His tag eg (His) 6 to (His) 10
- FLAG tag eg (His) 6 to (His) 10
- the polypeptide can be expressed as a fusion protein to which various tags such as HA tag and GFP are added.
- a well-known method such as electroporation, calcium phosphate method, liposome method, DEAE dextran method, microinjection, virus infection, lipofection, binding to a cell membrane-permeable peptide, etc. can be used. .
- known separation operations can be combined. For example, treatment with denaturing agents and surfactants such as urea, ultrasonic treatment, enzyme digestion, salting out and solvent fractional precipitation, dialysis, centrifugation, ultrafiltration, gel filtration, SDS-PAGE, isoelectric focusing, Examples include ion exchange chromatography, hydrophobic chromatography, affinity chromatography, and reverse phase chromatography.
- denaturing agents and surfactants such as urea, ultrasonic treatment, enzyme digestion, salting out and solvent fractional precipitation, dialysis, centrifugation, ultrafiltration, gel filtration, SDS-PAGE, isoelectric focusing.
- Polypeptides obtained by the above methods include those in the form of fusion proteins with other arbitrary proteins. Examples thereof include glutathione-S-transferase (GST) and a fusion protein with a His tag.
- GST glutathione-S-transferase
- a polypeptide in the form of a fusion protein is also included in the above-mentioned specific reactive addition polypeptide, and can be used in the first detection method of the present invention.
- the polypeptide expressed in the transformed cell may be subjected to various modifications in the cell after being translated.
- Such a post-translationally modified polypeptide can also be used in the first detection method of the present invention as long as it has a binding property to a polyclonal antibody against CAPRIN-1.
- translational modifications include elimination of N-terminal methionine, N-terminal acetylation, glycosylation, limited degradation by intracellular protease, myristoylation, isoprenylation, phosphorylation, and the like.
- Immunoassays themselves are well known in this field, and classified by reaction mode include sandwich method, competition method, agglutination method, Western blot method and the like.
- classification by label includes radioimmunoassay, fluorescent immunoassay, enzyme immunoassay, biotin immunoassay, and the like, and any method can be used to perform immunoassay of the antibody.
- the sandwich ELISA and the agglutination method can be preferably applied as an immunoassay method for the above-described antibody in the method of the present invention because it is easy to operate and does not require a large-scale apparatus.
- an enzyme When an enzyme is used as a label for an antibody, the enzyme is not particularly limited as long as it satisfies conditions such as a large turnover number, stability even when bound to an antibody, and specific coloring of a substrate.
- conditions such as a large turnover number, stability even when bound to an antibody, and specific coloring of a substrate.
- an enzyme inhibitor, a coenzyme, etc. can also be used.
- These enzymes and antibodies can be bound by a known method using a crosslinking agent such as a maleimide compound.
- a known substance can be used according to the type of enzyme used.
- the enzyme 33 ′, 5,5′-tetramethylbenzidine can be used, and when alkaline phosphatase is used as the enzyme, paranitrolphenol or the like can be used.
- the radioisotope those usually used in radioimmunoassay such as 125 I and 3 H can be used.
- the fluorescent dye those used in ordinary fluorescent antibody methods such as fluoroless isothiocyanate (FITC) and tetramethylrhodamine isothiocyanate (TRITC) can be used.
- FITC fluoroless isothiocyanate
- TRITC tetramethylrhodamine isothiocyanate
- the polypeptide used as an antigen is immobilized on a solid phase and serum or the like is used. Then, after washing, an appropriate secondary antibody is reacted. After washing, the secondary antibody bound to the solid phase is measured. Since the unbound secondary antibody can be easily removed by immobilizing the antigen polypeptide to the solid phase, it is preferable as an embodiment of the cancer detection method of the present invention.
- the secondary antibody for example, if the sample is derived from a dog, an anti-canine IgG antibody can be used.
- the secondary antibody bound to the solid phase can be measured.
- the amount of secondary antibody measured in this way corresponds to the amount of antibody in the serum sample.
- an enzyme used as the labeling substance
- the amount of antibody can be measured by adding a substrate that develops color by degradation by enzymatic action and optically measuring the amount of degradation of the substrate.
- a radioisotope used as the labeling substance, the radiation dose emitted by the radioisotope can be measured with a scintillation counter or the like.
- CAPRIN-1 that can be contained in a sample obtained from a living body is measured.
- the amount of antibody that undergoes an antigen-antibody reaction with CAPRIN-1 such as dogs and humans is significantly large, which means that the amount of accumulation of CAPRIN-1 as an antigen in cancer cells is significantly large. It is shown that.
- the fact that cancer can also be detected by measuring CAPRIN-1 itself is as specifically described in the Examples below. Accordingly, in vivo cancer can be detected by measuring CAPRIN-1 itself, as in the first method.
- Measurement of a polypeptide in a sample can be easily performed by a well-known immunoassay method. Specifically, for example, CAPRIN-1 that can exist in a sample is measured by preparing an antibody or antigen-binding fragment thereof that reacts with CAPRIN-1 in an antigen-antibody reaction and performing an immunoassay using the antibody. Can do.
- the antibody has cross-reactivity, for example, using only the canine CAPRIN-1 of SEQ ID NO: 6 using an antibody or an antigen-binding fragment thereof that reacts with the dog CAPRIN-1 of SEQ ID NO: 6
- the homologous factor in other mammals for example, human CAPRIN-1, feline CAPRIN-1, and the like of SEQ ID NO: 2 or 4
- the immunoassay method itself is a well-known conventional method as described above.
- CAPRIN-1 was found to be a cell membrane protein expressed on the surface of cancer cells. Since many proteolytic enzymes are contained in the cancer body, the portion of the CAPRIN-1 sequence that is expressed outside the cancer cell is decomposed and separated from the cancer cell in the cancer body. More than the portion of the CAPRIN-1 sequence that is expressed intracellularly in cancer cells. Therefore, if CAPRIN-1 antibodies or antigen-binding fragments thereof used in this measurement are those that bind to the cell surface of cancer cells, more CAPRIN-1 can be detected and cancer can be diagnosed with higher sensitivity. it can. Therefore, in the present invention, an antibody that binds to a portion of the CAPRIN-1 protein that is expressed on the cell surface of cancer cells is preferably used.
- the amino acid sequence represented by 61 (the amino acid sequence region represented by SEQ ID NO: 62 or 63 is preferred among the amino acid sequences represented by SEQ ID NO: 61), or 80% or more of the amino acid sequence, preferably Is an amino acid sequence having a sequence identity of 85% or more, more preferably 90% or more, and still more preferably 95% or more.
- antigen-binding fragment means an antibody fragment having the ability to bind to an antigen, such as a Fab fragment or F (ab ′) 2 fragment contained in an antibody molecule.
- the antibody may be a polyclonal antibody or a monoclonal antibody, but a monoclonal antibody with high reproducibility is preferred for immunoassay and the like.
- Methods for preparing polyclonal and monoclonal antibodies using a polypeptide as an immunogen are well known and can be easily performed by conventional methods. For example, an antibody against CAPRIN-1 is induced by immunizing an animal with an adjuvant using CAPRIN-1 bound to a carrier protein such as keyhole limpet hemocyan (KLH), casein, and serum albumin. can do.
- KLH keyhole limpet hemocyan
- a hybridoma is prepared by fusing an antibody-producing cell such as a spleen cell or lymphocyte collected from an immunized animal with a myeloma cell, and a hybridoma that produces an antibody that binds to CAPRIN-1 is selected and proliferated.
- a monoclonal antibody having CAPRIN-1 as a corresponding antigen can be obtained from the culture supernatant. The above method is a well-known ordinary method.
- mRNA encoding CAPRIN-1 that can be contained in a sample obtained from a living body is measured.
- mRNA encoding canine CAPRIN-1 of SEQ ID NO: 6, 8, 10, 12 or 14 or human CAPRIN-1 of SEQ ID NO: 2 or 4 is significantly higher in cancer cells. It is expressed. Therefore, in vivo cancer can also be detected by measuring the mRNA in the sample.
- the mRNA in the sample can be quantified by a conventional method such as real-time detection RT-PCR using the mRNA as a template, and can be generally quantified also by a staining intensity in a Northern blot which is a conventional method.
- polynucleotide for cancer detection a polynucleotide that specifically hybridizes with a partial region in the base sequence represented by an odd sequence number among SEQ ID NOs: 1 to 29 (hereinafter referred to as “polynucleotide for cancer detection”), It can be used as a probe or a primer in a nucleic acid amplification method to measure the abundance of the mRNA in a sample.
- any polynucleotide that specifically hybridizes to a partial region in the base sequence represented by an odd sequence number among SEQ ID NOs: 1 to 29 encodes CAPRIN-1 in mammals other than dogs and humans. MRNA can also be measured.
- the polynucleotide may be RNA or DNA.
- Normal hybridization conditions refers to conditions used for normal PCR annealing and probe detection.
- 50 mM KCl, 10 mM Tris- The reaction is carried out using a general buffer solution such as HCl (pH 8.3 to 9.0) and 1.5 mM MgCl 2 at an appropriate annealing temperature of about 54 ° C. to 60 ° C.
- a general buffer solution such as HCl (pH 8.3 to 9.0) and 1.5 mM MgCl 2
- annealing temperature of about 54 ° C. to 60 ° C.
- Northern High In the case of hybridization, 5 x SSPE, 50% formamide, 5 x Denhardt's solution, 0.1 to 0.5% SDS, or 0.1 to 5 x SSC, 0.1 to 0.5% SDS, A suitable hybridization temperature of about 42 ° C. to 65 ° C.
- a general hybridization solution such as In refers to carrying out a reaction. Further, after hybridization, washing is performed with, for example, 0.1 to 0.2 ⁇ SSC, 0.1% SDS.
- the appropriate annealing temperature or hybridization temperature is not limited to the above examples, and is determined based on the Tm value of the polynucleotide for cancer detection used as a primer or probe and the rule of thumb of the experimenter. Can be determined.
- “Substantially does not hybridize” means that it does not hybridize at all, or even if it is hybridized, it is much less than the amount hybridized to the target partial region, and hybridizes only in a relatively negligible amount. It means that.
- Examples of the polynucleotide that specifically hybridizes under such conditions include a polynucleotide having a certain sequence identity with the base sequence of the target partial region, for example, 70% or more, preferably 80% or more, A polynucleotide having a sequence identity of 85% or more, more preferably 90% or more, still more preferably 93% or more, still more preferably 95% or more, and still more preferably 98% or more.
- the polynucleotide has the same base sequence as that of the target partial region.
- sequence identity is the same as that of the amino acid sequence described above.
- the “partial sequence” refers to a partial sequence in the base sequence represented by an odd sequence number among SEQ ID NOs: 1 to 29, and is 15 consecutive bases or more, preferably 18 consecutive bases. More preferably, it is a sequence of 20 bases or more or 25 bases or more, more preferably 30, 40 or 50 bases or more.
- the term “base sequence shown in SEQ ID NO: 5” includes the base sequence actually shown in SEQ ID NO: 5 as well as a complementary sequence thereto.
- polynucleotide having the base sequence shown in SEQ ID NO: 5 a single-stranded polynucleotide having the base sequence actually shown in SEQ ID NO: 5, its complementary base sequence And double-stranded polynucleotides comprising these.
- any one of the nucleotide sequences will be appropriately selected. You can easily make that choice.
- the number of bases of the polynucleotide for cancer detection is preferably 18 bases or more from the viewpoint of ensuring specificity.
- the size is preferably 18 bases or more, more preferably 20 bases or more and preferably not more than the entire length of the coding region.
- the size is preferably 18 bases or more, and preferably 50 bases or less.
- Preferable examples of the polynucleotide for cancer detection include polynucleotides consisting of 18 or more consecutive bases in the base sequence represented by the odd sequence number among SEQ ID NOs: 1 to 29.
- SEQ ID NOs: 5, 7, 9, 11 may be used to determine the amount of mRNA encoding canine CAPRIN-1 of SEQ ID NO: 6, 8, 10, 12 or 14.
- a polynucleotide that specifically hybridizes with a partial region in 13 is used, and for measuring the amount of mRNA encoding human CAPRIN-1 of SEQ ID NO: 2 or 4, the partial region in SEQ ID NO: 1 or 3 is used.
- a polynucleotide that specifically hybridizes with is used.
- a protein derived from one mammal and its homologous factor derived from another mammal usually have high sequence identity even at the base sequence level, and the sequence identity with the base sequences of SEQ ID NOS: 1 to 13 is also 94-100. % And very high. Therefore, for example, a polynucleotide that specifically hybridizes with a partial region in SEQ ID NO: 5 can specifically hybridize with a partial region in an odd sequence number among SEQ ID NOS: 1 to 29 corresponding to the partial region. .
- a polynucleotide that specifically hybridizes with a partial region in SEQ ID NO: 5 not only mRNA encoding canine CAPRIN-1 in SEQ ID NO: 6, but also human CAPRIN-1 in SEQ ID NO: 2 or 4
- mRNA encoding CAPRIN-1 of other mammals such as cats can also be measured.
- a partial region having a particularly high sequence identity is selected between the respective SEQ ID NOs (odd SEQ IDs: 1 to 29). It is more desirable.
- a method for measuring a test nucleic acid using a polynucleotide that specifically hybridizes with a partial region of the test nucleic acid as a primer or probe for a nucleic acid amplification method such as PCR is well known.
- a nucleic acid amplification method such as PCR
- Northern blot, in situ hybridization and the like can be mentioned.
- any of these well-known measurement methods can be employed.
- Nucleic acid amplification methods such as PCR are well known in this field, and reagent kits and devices for that purpose are also commercially available and can be easily performed. That is, for example, a test nucleic acid to be a template (for example, cDNA of a gene encoding a protein having an amino acid sequence represented by an even sequence number among SEQ ID NOs: 2 to 30) and a polynucleotide (primer) for cancer detection
- a test nucleic acid to be a template for example, cDNA of a gene encoding a protein having an amino acid sequence represented by an even sequence number among SEQ ID NOs: 2 to 30
- a polynucleotide primer
- the denaturation step is 90 to 95 ° C.
- the annealing step is Tm of the template and the primer or in the vicinity thereof (preferably within ⁇ 4 ° C.)
- the extension step is the optimum temperature of a thermostable DNA polymerase such as Taq polymerase or Pfu polymerase.
- a thermostable DNA polymerase such as Taq polymerase or Pfu polymerase.
- Each step is appropriately selected in about 30 seconds to 2 minutes.
- the nucleic acid amplification method is not limited to PCR, and other nucleic acid amplification methods well known in this field can also be used.
- the test nucleic acid when nucleic acid amplification is performed using a pair of polynucleotides for cancer detection as primers and a test nucleic acid as a template, the test nucleic acid is amplified, whereas the sample contains the test nucleic acid. If not, amplification does not occur, and it can be determined whether or not the test nucleic acid is present in the sample by detecting the amplification product. Amplification products can be detected by electrophoresis of the reaction solution after amplification and staining the band with ethidium bromide, etc., or by immobilizing the amplified product on a solid phase such as nylon membrane, and specific to the test nucleic acid.
- test nucleic acid can be semi-quantified based on the intensity of the electrophoresis band.
- the test nucleic acid may be mRNA or cDNA reverse transcribed from mRNA.
- the NASBA method 3SR method, TMA method
- the NASBA method itself is well known, and kits therefor are also commercially available, so that it can be easily carried out using the above pair of primers.
- a labeled probe obtained by attaching a label such as a fluorescent label, a radiolabel, or a biotin label to a polynucleotide for cancer detection can be used.
- the polynucleotide labeling method itself is well known.
- To examine whether the test nucleic acid is present in the sample by immobilizing the test nucleic acid or its amplification product, hybridizing with the labeled probe, washing, and measuring the label bound to the solid phase Can do.
- the polynucleotide for cancer detection bound to the solid phase is also called a probe.
- a method for measuring a test nucleic acid using a polynucleotide probe is also well known in this field, and the polynucleotide probe is brought into contact with the test nucleic acid at or near Tm (preferably within ⁇ 4 ° C.) in a buffer solution. And washing, and then measuring the template nucleic acid bound to the hybridized labeled probe or solid phase probe.
- Tm preferably within ⁇ 4 ° C.
- Such methods include well-known methods such as Northern blot, in situ hybridization, Southern blot. In the present invention, any known method can be applied.
- whether or not the target animal has cancer is determined based on the expression level of CAPRIN-1 measured as described above. Cancer can be detected only by measuring the expression of CAPRIN-1 in the target animal.
- the expression level of CAPRIN-1 antibody level, poly It is preferable to obtain a healthy subject reference value by examining the peptide amount or mRNA amount, and compare the measured value of the target animal with the healthy subject reference value.
- the CAPRIN-1 expression level is examined for samples obtained from a large number of patients who are known to have cancer, and a cancer patient reference value is obtained. May be compared with both the healthy person reference value and the cancer patient reference value.
- the reference value can be determined, for example, by quantifying the CAPRIN-1 expression level in each sample and calculating the average value.
- the healthy person reference value and the cancer patient reference value can be determined in advance by examining the expression level of CAPRIN-1 for a large number of healthy persons and cancer patients. Therefore, when comparing with a reference value by the method of the present invention, a predetermined reference value may be used.
- diagnosis using other cancer antigens or cancer markers may be combined.
- the detection accuracy of cancer can further be improved.
- another polypeptide that is highly expressed in cancer tissue can be used in combination as an antigen in the same manner as the above-described polypeptide. .
- cancer in vivo can be detected.
- the method of the present invention can detect small-sized tumors that are invisible to eyes and tumors in the deep part of the body, which is useful for early detection of cancer.
- the detection method of the present invention is applied to a patient who is being followed up after treatment for cancer, the cancer can be detected at an early stage when the cancer recurs.
- the accumulation amount of the protein and its mRNA in the living body increases, and the CAPRIN in the serum increases.
- Many antibodies against -1 are produced.
- the amount of accumulation of the protein and its mRNA in the living body decreases, and the antibody against CAPRIN-1 in serum decreases. Therefore, when the amount of CAPRIN-1 expressed is greater than that of the control, it can be determined that tumor growth or cancer metastasis has occurred, that is, the degree of progression of cancer has progressed.
- an increase in the amount of the antibody in the serum bearing cancer has been observed with the progression of cancer (malignant type) such as tumor growth or metastasis.
- cancer malignant type
- the degree of progression of cancer can also be detected.
- the malignant type has a significantly higher amount of the antibody than the benign type. Therefore, when the expression level of CAPRIN-1 is large, it can be determined that the malignancy of cancer is higher. That is, according to the method of the present invention, the malignancy of cancer can also be detected.
- the cancer that is the target of the cancer detection method of the present invention is a cancer that expresses CAPRIN-1, and is a brain tumor, head, neck, lung, uterus, or squamous cell carcinoma of the esophagus, melanoma, lung, or uterus.
- Specimens used in the method of the present invention include blood, serum, plasma, ascites, pleural effusion and other body fluids, tissues, and cells.
- serum, plasma, ascites and pleural effusion can be preferably used in the first method and the second method, and a tissue sample and a cell sample are preferable in the third method for measuring mRNA. .
- the above-mentioned polypeptide used as an immunoassay antigen in the first method canine CAPRIN-1 of SEQ ID NO: 2 and its homologous factor, specific reactive partial polypeptide, specific reactive modified polypeptide, and specific reactivity
- the additional polypeptide can be provided as a cancer detection reagent.
- the reagent may consist only of the above polypeptide, and may contain various additives useful for stabilizing the polypeptide.
- the reagent can also be provided in a state immobilized on a solid phase such as a plate or a membrane. Preferred examples of the polypeptide are as described above.
- An antibody or antigen-binding fragment thereof that reacts with CAPRIN-1 for antigen-antibody reaction which is used in immunoassay of CAPRIN-1 itself by the second method, can also be provided as a cancer detection reagent.
- the cancer detection reagent in this case may also consist only of the antibody or antigen-binding fragment, and may contain various additives useful for stabilizing the antibody or antigen-binding fragment. Good.
- the antibody or antigen-binding fragment may be one obtained by binding a metal such as manganese or iron. When such a metal-binding antibody or antigen-binding fragment is administered into the body, a larger amount of the antibody or antigen-binding fragment accumulates at a site where a larger amount of antigen protein exists. The presence of cancer cells that produce the protein can be detected.
- the above-mentioned cancer detection polynucleotide used for mRNA measurement by the third method can also be provided as a cancer detection reagent.
- the cancer detection reagent may be composed of only the polynucleotide, and may contain various additives useful for stabilizing the polynucleotide.
- the cancer detection polynucleotide contained in the reagent is preferably a primer or a probe. The conditions and preferred examples of the polynucleotide for cancer detection are as described above.
- Example 1 Acquisition of novel cancer antigen protein by SEREX method (1) Preparation of cDNA library Total RNA was extracted from testicular tissue of healthy dogs by the acid guanidinium-phenol-chloroform method (Acid guanidinium-Phenol-Chloroform method). PolyA RNA was purified using Oligotex-dT30 mRNA purification Kit (Takara Shuzo) according to the protocol attached to the kit.
- a dog testis cDNA phage library was synthesized using the obtained mRNA (5 ⁇ g).
- the cDNA phage library was prepared using cDNA Synthesis Kit, ZAP-cDNA Synthesis Kit, ZAP-cDNA GigapackIII Gold Cloning Kit (manufactured by STRATAGENE) according to the protocol attached to the kit.
- the size of the prepared cDNA phage library was 7.73 ⁇ 10 5 pfu / ml.
- the membrane was recovered, immersed in TBS (10 mM Tris-HCl, 150 mM NaCl pH 7.5) containing 0.5% nonfat dry milk, and shaken at 4 ° C. overnight to suppress nonspecific reaction.
- TBS 10 mM Tris-HCl, 150 mM NaCl pH 7.5
- This filter was reacted with serum of a patient dog diluted 500 times at room temperature for 2 to 3 hours.
- the serum pretreatment method is as follows. That is, ⁇ ZAP Express phage into which no foreign gene was inserted was infected with host E. coli (XL1-BLue MRF ′), and then cultured overnight at 37 ° C. on NZY plate medium. Next, a buffer of 0.2 M NaHCO 3 pH 8.3 containing 0.5 M NaCl was added to the plate and allowed to stand at 4 ° C. for 15 hours, and then the supernatant was recovered as an E. coli / phage extract. Next, the recovered E.
- coli / phage extract was passed through an NHS-column (GE Healthcare Bio-Science) to immobilize the E. coli / phage derived protein.
- Serum dog serum was passed through and reacted with this protein-immobilized column, and antibodies adsorbed to E. coli and phage were removed from the serum.
- the serum fraction passed through the column was diluted 500 times with TBS containing 0.5% nonfat dry milk, and this was used as an immunoscreening material.
- phagemid host Escherichia coli prepared to have an absorbance OD 600 of 1.0 and 10 ⁇ l of the purified phage solution were mixed and reacted at 37 ° C. for 15 minutes, and 50 ⁇ l was treated with ampicillin (final concentration 50 ⁇ g / ml).
- SOLR phagemid host Escherichia coli
- the purified plasmid was analyzed for the full-length insert sequence by the primer walking method using the T3 primer shown in SEQ ID NO: 31 and the T7 primer shown in SEQ ID NO: 32.
- the gene sequences described in SEQ ID NOs: 5, 7, 9, 11, and 13 were obtained by this sequence analysis.
- the homology search program BLAST search http://www.ncbi.nlm.nih.gov/BLAST/
- BLAST search http://www.ncbi.nlm.nih.gov/BLAST/
- sequence identity of this gene with the gene encoding the human homologous factor was 94% for the nucleotide sequence and 98% for the amino acid sequence in the region translated into protein.
- the base sequences of human homologous factors are shown in SEQ ID NOs: 1 and 3, and amino acid sequences are shown in SEQ ID NOs: 2 and 4.
- sequence identity of the obtained canine gene with the gene encoding the bovine homologous factor was 94% for the nucleotide sequence and 97% for the amino acid sequence in the region translated into protein.
- the base sequence of the bovine homologous factor is shown in SEQ ID NO: 15, and the amino acid sequence is shown in SEQ ID NO: 16.
- sequence identity between the gene encoding the human homologous factor and the gene encoding the bovine homologous factor was 94% in the base sequence and 93-97% in the amino acid sequence in the region translated into the protein. Further, the sequence identity of the obtained canine gene with the gene encoding the equine homologous factor was 93% nucleotide sequence and 97% amino acid sequence in the region translated into protein.
- the base sequence of the equine homologous factor is shown in SEQ ID NO: 17, and the amino acid sequence is shown in SEQ ID NO: 18.
- sequence identity between the gene encoding the human homologous factor and the gene encoding the equine homologous factor was 93% nucleotide sequence and 96% amino acid sequence in the region translated into protein.
- sequence identity of the obtained canine gene with the gene encoding the mouse homologous factor was 87 to 89% of the base sequence and 95 to 97% of the amino acid sequence in the region translated into the protein.
- the base sequence of the mouse homologous factor is shown in SEQ ID NO: 19, 21, 23, 25, 27, and the amino acid sequence is shown in SEQ ID NO: 20, 22, 24, 26, 28.
- sequence identity between the gene encoding the human homologous factor and the gene encoding the mouse homologous factor was 89 to 91% of the base sequence and 95 to 96% of the amino acid sequence in the region translated into the protein.
- sequence identity with the gene which codes the chicken homologous factor of the acquired canine gene was the base sequence 82% and the amino acid sequence 87% in the area
- the nucleotide sequence of the chicken homologous factor is shown in SEQ ID NO: 29, and the amino acid sequence is shown in SEQ ID NO: 30.
- the sequence identity between the gene encoding the human homologous factor and the gene encoding the chicken homologous factor was 81 to 82% of the base sequence and 86% of the amino acid sequence in the region translated into the protein.
- the above gene-specific primers are 206 to 632 in the nucleotide sequence of SEQ ID NO: 5 (canine CAPRIN-1 gene) and 698 to 1124 in the nucleotide sequence of SEQ ID NO: 1 (human CAPRIN-1 gene). It was intended to amplify the base region.
- GAPDH specific primers (described in SEQ ID NOs: 35 and 36) were also used. As a result, as shown in FIG. 1, strong expression was observed in testis in healthy dog tissues, while expression was observed in canine breast cancer and adenocarcinoma tissues.
- the expression of the human homologous factor of the obtained gene was also confirmed, it was found only in the testis that the expression was confirmed in normal tissues as in the canine CAPRIN-1 gene, but in cancer cells, breast cancer, brain tumor, leukemia Expression was detected in many types of cancer cell lines such as lung cancer and esophageal cancer cell lines, and in particular, expression was confirmed in many breast cancer cell lines. From this result, it was confirmed that CAPRIN-1 was not expressed in normal tissues other than testis, but was expressed in many cancer cells, particularly in breast cancer cell lines.
- reference number 1 on the vertical axis indicates the expression pattern of the gene identified above, and reference number 2 indicates the expression pattern of the GAPDH gene as a comparative control.
- Each organ was cut in PBS and fixed at reflux overnight with 0.1 M phosphate buffer (pH 7.4) containing 4% paraformaldehyde (PFA). The reflux solution is discarded, and the tissue surface of each organ is rinsed with PBS.
- a PBS solution containing 10% sucrose is placed in a 50 ml centrifuge tube, and each tissue is placed therein and shaken at 4 ° C. for 2 hours using a rotor. That ’s it.
- the solution was replaced with a PBS solution containing 20% sucrose, allowed to stand at 4 ° C. until the tissue subsided, then replaced with a PBS solution containing 30% sucrose, and allowed to stand at 4 ° C. until the tissue subsided.
- the tissue was removed and the necessary part was cut out with a scalpel.
- an OCT compound manufactured by Tissue Tek
- Cryomold is placed on dry ice and rapidly frozen, then sliced into 10-20 ⁇ m using a cryostat (LEICA) and air-dried with a hair dryer for 30 minutes together with the slide glass, and the sliced tissue is placed.
- a slide glass was prepared.
- an operation of replacing PBS-T every 5 minutes in a staining bottle filled with PBS-T (physiological saline containing 0.05% Tween 20) was performed three times.
- the mouse tissue was MOM mouse Ig blocking reagent (VECTASTAIN), and the dog tissue was 10% fetal bovine serum.
- VECTASTAIN MOM mouse Ig blocking reagent
- Each PBS-T solution was placed and allowed to stand for 1 hour at room temperature on a moist chamber.
- the monoclonal antibody (monoclonal antibody # 8) against CAPRIN-1 having the heavy chain variable region of SEQ ID NO: 55 and the light chain variable region of SEQ ID NO: 56, which reacts with the surface of the cancer cell prepared in Example 3, is blocked.
- the solution prepared to 10 ⁇ g / ml with the solution was placed and allowed to stand overnight at 4 ° C.
- MOM biotin-labeled anti-IgG antibody VECTASTAIN
- MOM biotin-labeled anti-IgG antibody VECTASTAIN
- avidin-biotin ABC reagent manufactured by VECTASTAIN was placed and allowed to stand at room temperature for 5 minutes in a moist chamber.
- a DAB coloring solution (DAB 10 mg + 30% H 2 O 2 10 ⁇ l / 0.05 M Tris-HCl (pH 7.6) 50 ml) was placed and placed in a moist chamber at room temperature for 30 minutes. Let stand for a minute. After rinsing with distilled water, a hematoxylin reagent (manufactured by DAKO) was placed and allowed to stand at room temperature for 1 minute, and then rinsed with distilled water. Each of the 70%, 80%, 90%, 95%, and 100% ethanol solutions was sequentially placed for 1 minute, and then allowed to stand overnight in xylene.
- the slide glass was taken out and sealed with Glycergel Mounting Medium (manufactured by DAKO) and then observed.
- Glycergel Mounting Medium manufactured by DAKO
- CAPRIN-1 was slightly expressed in cells in the salivary gland, kidney, colon, and stomach tissues, but was not observed on the cell surface, and in tissues derived from other organs. No expression was observed.
- Example 2 Production of Canine and Human Novel Cancer Antigen Protein
- a recombinant protein was produced by the following method. For PCR, 1 ⁇ l of a vector prepared from the phagemid solution obtained in Example 1 and subjected to sequence analysis, 2 types of primers containing NdeI and KpnI restriction enzyme cleavage sequences (described in SEQ ID NOs: 37 and 38) were each treated with 0.
- the purified DNA fragment was ligated to the cloning vector pCR-Blunt (manufactured by Invitrogen). After transforming this into E. coli, the plasmid was recovered, and it was confirmed by sequencing that the amplified gene fragment matched the target sequence. A plasmid corresponding to the target sequence was treated with NdeI and KpnI restriction enzymes, purified with QIAquick Gel Extraction Kit, and then inserted into the expression vector pET30b (manufactured by Novagen) for E. coli treated with NdeI and KpnI restriction enzymes. . By using this vector, a His-tagged recombinant protein can be produced. This plasmid was transformed into E. coli BL21 (DE3) for expression, and the target protein was expressed in E. coli by inducing expression with 1 mM IPTG.
- a canine homologous gene recombinant protein was prepared by the following method.
- 1 ⁇ l of the cDNA whose expression by RT-PCR method was confirmed from various tissue / cell cDNA prepared in Example 1 and two kinds of primers containing NdeI and KpnI restriction enzyme cleavage sequences (described in SEQ ID NOs: 39 and 40).
- the purified DNA fragment was ligated to the cloning vector pCR-Blunt (manufactured by Invitrogen). After transforming this into E. coli, the plasmid was recovered, and it was confirmed by sequencing that the amplified gene fragment matched the target sequence. A plasmid corresponding to the target sequence was treated with NdeI and KpnI restriction enzymes, purified with QIAquick Gel Extraction Kit, and then inserted into the expression vector pET30b (manufactured by Novagen) for E. coli treated with NdeI and KpnI restriction enzymes. . By using this vector, a His-tagged recombinant protein can be produced. This plasmid was transformed into E. coli BL21 (DE3) for expression, and the target protein was expressed in E. coli by inducing expression with 1 mM IPTG.
- a recombinant protein of human homologous gene was prepared by the following method. PCR was performed using 1 ⁇ l of cDNA that could be confirmed by RT-PCR method from various tissue and cell cDNAs prepared in Example 1, and two kinds of primers containing SacI and XhoI restriction enzyme cleavage sequences (described in SEQ ID NOs: 41 and 42). ) To 0.4 ⁇ M, 0.2 mM dNTP, 1.25 U PrimeSTAR HS polymerase (Takara Shuzo), add each reagent and attached buffer to make the total volume 50 ⁇ l, and use Thermal Cycler (BIO RAD).
- the purified DNA fragment was ligated to the cloning vector pCR-Blunt (manufactured by Invitrogen). After transforming this into E. coli, the plasmid was recovered, and it was confirmed by sequencing that the amplified gene fragment matched the target sequence.
- a plasmid corresponding to the target sequence was treated with SacI and XhoI restriction enzymes, purified with QIAquick Gel Extraction Kit, and then inserted into an expression vector pET30a (manufactured by Novagen) for Escherichia coli treated with SacI and XhoI restriction enzymes. .
- This vector a His-tagged recombinant protein can be produced.
- This plasmid was transformed into E. coli BL21 (DE3) for expression, and the target protein was expressed in E. coli by inducing expression with 1 mM IPTG.
- the cells were suspended in phosphate buffered physiological saline and sonicated on ice.
- the E. coli sonication solution was centrifuged at 6000 rpm for 20 minutes, and the resulting supernatant was used as a soluble fraction and the precipitate was used as an insoluble fraction.
- the soluble fraction was applied to a nickel chelate column (carrier: Chelating Sepharose (trademark) Fast Flow (GE Health Care), column volume 5 mL, 50 mM hydrochloric acid buffer (pH 8.0) as an equilibration buffer) prepared according to a conventional method. Added. The unadsorbed fraction was washed with 10 mM column volume of 50 mM hydrochloric acid buffer (pH 8.0) and 20 mM imidazole-containing 20 mM phosphate buffer (pH 8.0), and immediately, 100 mM imidazole-containing 20 mM. Six beds were eluted with phosphate buffer (pH 8.0).
- carrier: Q Sepharose (trademark) Fast Flow (GE Health Care), column) A volume of 5 mL was added to 20 mM phosphate buffer (pH 8.0) as an equilibration buffer.
- the unadsorbed fraction was washed with 20 mM phosphate buffer solution (pH 7.0) 10 times the column volume and 20 mM phosphate buffer solution (pH 7.0) containing 200 mM sodium chloride, and immediately, 400 mM chloride was added.
- Example 3 Production of Antibody against CAPRIN-1 (1) Production of Polyclonal Antibody against CAPRIN-1 Derived Peptide To obtain an antibody that binds to CAPRIN-1, a CAPRIN-1 derived peptide (Arg-Asn-Leu-Glu- Lys-Lys-Lys-Gly-Lys-Leu-Asp-Asp-Tyr-Gln (SEQ ID NO: 43)) was synthesized. 1 mg of this peptide was mixed with an equal volume of incomplete Freund's adjuvant (IFA) solution as an antigen, and this was administered subcutaneously to rabbits 4 times every 2 weeks. Thereafter, blood was collected to obtain an antiserum containing a polyclonal antibody.
- IFA incomplete Freund's adjuvant
- this antiserum was purified using a protein G carrier (manufactured by GE Healthcare Bioscience) to obtain a polyclonal antibody against the CAPRIN-1-derived peptide.
- a protein G carrier manufactured by GE Healthcare Bioscience
- the reactivity of the obtained polyclonal antibody to the breast cancer cell surface was examined. Specifically, 10 6 human breast cancer cell lines MDA-MB-231V were centrifuged in a 1.5 ml microcentrifuge tube, and 0.1% fetal bovine serum (FBS) containing the polyclonal antibody was added thereto. PBS solution was added and left on ice for 1 hour.
- FBS fetal bovine serum
- the operation was repeated three times to obtain spleen cells.
- the obtained spleen cells and mouse myeloma cells SP2 / 0 (purchased from ATCC) were mixed at a ratio of 10: 1, and 200 ⁇ l of RPMI 1640 medium containing 10% FBS heated to 37 ° C. and PEG 1500 (Boehringer) PEG solution prepared by mixing 800 ⁇ l was added and allowed to stand for 5 minutes for cell fusion.
- the cells were suspended in 150 ml of RPMI 1640 medium (HAT selective medium) containing 15% FBS to which 2% equivalent of Gibco's HAT solution was added, and a 96-well plate (NUNC) 100 ⁇ l per well of (made) was seeded on 15 plates.
- RPMI 1640 medium HAT selective medium
- NUNC 96-well plate
- Hybridomas were selected using as an index the binding affinity of the antibody produced by the prepared hybridomas to the CAPRIN-1 protein.
- 100 ⁇ l of 1 ⁇ g / ml of the CAPRIN-1 protein solution prepared in Example 2 was added per well of a 96-well plate and allowed to stand at 4 ° C. for 18 hours. Each well was washed 3 times with PBS-T, and then added with 400 ⁇ l of 0.5% Bovine Serum Albumin (BSA) solution (manufactured by Sigma) per well and allowed to stand at room temperature for 3 hours.
- BSA Bovine Serum Albumin
- hybridomas were added to the plate at a ratio of 0.5 per well of the 96-well plate and cultured. One week later, hybridomas forming a single colony in the well were observed. The cells in these wells were further cultured, and hybridomas were selected using the binding affinity of the antibody produced by the cloned hybridomas to the CAPRIN-1 protein as an index. 100 ⁇ l of 1 ⁇ g / ml of the CAPRIN-1 protein solution prepared in Example 2 was added per well of a 96-well plate and allowed to stand at 4 ° C. for 18 hours. After each well was washed 3 times with PBS-T, 400 ⁇ l of 0.5% BSA solution was added per well and allowed to stand at room temperature for 3 hours.
- the monoclonal antibody # 1 is composed of a heavy chain variable region of SEQ ID NO: 44 and a light chain variable region of SEQ ID NO: 45
- # 2 is a heavy chain variable region of SEQ ID NO: 44 and a light chain variable region of SEQ ID NO: 46.
- # 3 consists of the heavy chain variable region of SEQ ID NO: 44 and the light chain variable region of SEQ ID NO: 47
- # 4 consists of the heavy chain variable region of SEQ ID NO: 44 and the light chain variable region of SEQ ID NO: 48
- # 5 consists of a heavy chain variable region of SEQ ID NO: 49 and a light chain variable region of SEQ ID NO: 50
- # 6 consists of a heavy chain variable region of SEQ ID NO: 51 and a light chain variable region of SEQ ID NO: 52
- # 7 consists of a heavy chain variable region of SEQ ID NO: 53 and a light chain variable region of SEQ ID NO: 54
- # 8 consists of a heavy chain variable region of SEQ ID NO: 55 and a light chain variable region of SEQ ID NO: 56
- # 9 consists of the heavy chain variable region of SEQ ID NO: 57 and SEQ ID NO: 58
- # 10 consisting of 60 light chain variable region of: 59 heavy chain variable region SEQ ID NO.
- DTT (manufactured by Fluka) is added to 100 ⁇ l of a recombinant CAPRIN-1 protein solution dissolved in PBS to a concentration of 1 ⁇ g / ⁇ l so as to have a final concentration of 10 mM. Reduction of the disulfide bond in one protein was performed, and then iodoacetamide (manufactured by Wako Pure Chemical Industries, Ltd.) having a final concentration of 20 mM was added, and an alkylation reaction of a thiol group was performed for 30 minutes at 37 ° C. under light shielding conditions.
- trypsin manufactured by Promega
- 1% BSA manufactured by Sigma
- Protein A-glass beads was previously added
- the antigen-antibody complex was eluted using 100 ⁇ l of 0.1% formic acid, and Q-TOF Premier (manufactured by Waters-MicroMass) was used as the eluate. LC-MS analysis was performed using this. Analysis followed the protocol attached to the instrument.
- polypeptide of SEQ ID NO: 61 was identified as a partial sequence of CAPRIN-1 recognized by any of the monoclonal antibodies against CAPRIN-1 of # 1 to # 10. Furthermore, the peptide of SEQ ID NO: 62 was identified as a partial sequence in the polypeptide of SEQ ID NO: 61 recognized by the monoclonal antibodies # 1 to # 4, # 5 to # 7 and # 9, and the partial sequence peptide It was found that monoclonal antibody # 1 to # 4 recognize the peptide of SEQ ID NO: 63.
- Example 4 Cancer diagnosis using CAPRIN-1 polypeptide (1) Cancer diagnosis of dogs Blood was collected from 342 diseased dogs and 6 healthy dogs with confirmed malignant or benign tumors, and serum was separated. Using the canine CAPRIN-1 polypeptide (SEQ ID NO: 8) prepared in Example 2 and an anti-canine IgG antibody, the IgG antibody titer in serum specifically reacting with the polypeptide was measured by ELISA.
- the prepared polypeptide was solid-phased by adding 100 ⁇ l / well of a recombinant protein solution diluted to 5 ⁇ g / mL with phosphate buffered saline to a 96-well immobilizer amino plate (manufactured by Nunk) at 4 ° C. I left it overnight.
- 0.5% BSA bovine serum albumin (bovine serum albumin), Sigma-Aldrich Japan) containing 50 mM sodium bicarbonate buffer solution (pH 8.4) (hereinafter blocking solution) was added at 100 ⁇ l / well at room temperature. Shake for 1 hour.
- malignant melanoma malignant mixed tumor, hepatocellular carcinoma, basal cell carcinoma, sputum cell-like gingival tumor, intraoral mass, perianal adenocarcinoma, anal cyst mass, anal sac apocrine adenocarcinoma, Sertoli cell tumor , Vaginal vestibular cancer, sebaceous gland cancer, sebaceous gland epithelioma, sebaceous adenoma, sweat gland cancer, intranasal adenocarcinoma, nasal gland cancer, thyroid cancer, colon cancer, bronchial adenocarcinoma, adenocarcinoma, ductal carcinoma, breast cancer, complex type Mammary adenocarcinoma, malignant mixed mammary tumor, intraductal papillary adenocarcinoma, fibrosarcoma, hemangioperiosteum, osteosarcoma, chondrosarcoma, soft tissue sarcoma, his
- the serum derived from these cancer-bearing dogs showed a significantly high antibody titer against the recombinant protein as shown in FIG.
- the 108 types of cancer types are as follows. Although some specimens suffer from multiple types of cancer, the numerical values shown below are cumulative values for each type of cancer.
- diagnosis such as cancer diagnosis, progression diagnosis, malignancy diagnosis, postoperative follow-up diagnosis, recurrence diagnosis, metastasis diagnosis, etc. of the invisible part may be possible. all right.
- diagnosis such as cancer diagnosis, progression diagnosis, malignancy diagnosis, postoperative follow-up diagnosis, recurrence diagnosis, metastasis diagnosis, etc. of the invisible part may be possible. all right.
- dog 2 (beagle) diagnosed with basal cell carcinoma (malignant) had an absorbance at 450 nm of 0.04.
- the dog 3 (mongrel) diagnosed as having a folliculoma (benign) showed no absorbance at 450 nm detected at all. Therefore, it was found that malignant basal cell carcinoma and benign type blastoma can be diagnosed with the same basal cell tumor.
- Breast tumors include malignant tumors such as breast cancer and mixed malignant breast tumors, and benign breast tumors that do not show malignant findings.
- Patient Dog 4 (Shetland Sheepdog) is a patient who underwent surgery for breast cancer on July 17, 2007. There were three tumors in Patient Dog 4, and the pathological diagnosis using the excised tissue all had the same diagnosis name. Breast tissue with strong atypia and invasiveness was somewhat widespread papillary-glandular-proliferating and vascular invasion was also confirmed on the specimen, so it was diagnosed as breast cancer with a high degree of malignancy. As a result of serodiagnosis collected at the time of surgery, the absorbance at 450 nm was 0.41.
- Patient Dog 5 was a patient who had undergone a breast tumor removal operation on October 9, 2007.
- a tumor in which both mammary epithelial cells and myoepithelial cell components proliferated was formed, but the myoepithelial cell components were uniform spindle cells and no malignant findings were observed.
- the glandular epithelial cell component was diagnosed as benign mammary adenoma with slight malignancy and nuclear atypia but no malignant findings.
- the absorbance at 450 nm was zero.
- a tumor with high malignancy has a higher value than a tumor with low malignancy, that is, a benign tumor.
- breast cancer malignant tumors
- breast cancer mixed breast tumor and 21 benign breast tumors that did not show malignant findings
- breast cancer specimens showed a high value distribution.
- the diagnosis was probably a lymphoma due to metastasis.
- the absorbance at 450 nm increased to 0.10, which was found to be a metastasis of a previously existing tumor.
- Patient Dog 10 is a patient dog whose tumor was removed by malignant melanoma of the right lip on March 11, 2006. From June 10, 2006 to September 26, 2006, he had a history of treatment with an anticancer drug (cyclophosphaside), and since May 23, 2006, he has been taking Biremo S based on organic germanium.
- an anticancer drug cyclophosphaside
- Biremo S based on organic germanium.
- the absorbance at 450 nm was hardly detected as 0.03.
- metastatic malignant melanoma is diagnosed.
- the metastasis occurred again on June 27, 2007, 3 months after the operation of the metastasized black species.
- a tumor occurred in the right cervical region, but on June 27, 2007, it occurred on the opposite side, and the shape of the tumor also formed a black mass similar to the previous one. is there.
- the size is 3.1 ⁇ 3.2 ⁇ 0.8 cm large, and it is a metastasis in clinical diagnosis.
- the absorbance at 450 nm increased to 0.23, and it was found to be metastasis of a previously existing tumor.
- Patient Dog 11 (Shizyu) was a patient who had undergone a breast cancer extraction operation on June 21, 2007.
- the mammary gland tissue with strong atypia and invasiveness grows in a large and small mass in the form of adenoid-tubular-papillary, mixed with the slight growth of fibrous connective tissue. Diagnosed as breast cancer with moderate malignancy.
- the absorbance of this dog 11 at 450 nm was 0.26.
- Patient cat 1 (mongrel) was a patient who underwent surgery to remove the tumor for breast cancer on May 8, 2007. Absorbance of the cat 1 at 450 nm was 0.21. In addition, the absorbance at 450 nm was 0.18 in the cat 2 (Himalayan) who underwent surgery for ductal carcinoma on October 17, 2006. On the other hand, it was not detected at all in healthy cats.
- Blocking was performed by adding 100 ⁇ l / well of a solution obtained by dissolving 4 g of Block Ace powder (DS Pharma Biomedical Co., Ltd.) in 100 ml of purified water and diluting 4 times with purified water (hereinafter referred to as blocking solution) for 1 hour at room temperature. Shake. 100-fold dilution / well of a 1000-fold diluted serum using a blocking solution was added for dilution, and the reaction was performed by shaking at room temperature for 3 hours.
- Block Ace powder DS Pharma Biomedical Co., Ltd.
- HRP-modified anti-human IgG antibody HRP--washed 3 times with phosphate buffered saline (hereinafter PBS-T) containing 0.05% Tween 20 (manufactured by Wako Pure Chemical Industries, Ltd.) and diluted 10,000 times with blocking solution 100 ⁇ l / well of Goat Anti-Human IgG (H + L) Conjugate: manufactured by Zymed Laboratories) was added, and the reaction was performed by shaking at room temperature for 1 hour. After washing 3 times with PBS-T, 100 ⁇ l / well of HRP substrate TMB (1-Step Turbo TMB (tetramethylbenzidine), PIERCE) was added and allowed to react at room temperature for 30 minutes.
- HRP substrate TMB (1-Step Turbo TMB (tetramethylbenzidine), PIERCE
- 17 human serum samples purchased from Promeddx
- human-derived cancer antigen protein amino acid sequence of SEQ ID NO: 3
- the IgG antibody titer in the sera that react spontaneously was measured.
- the absorbance at 450 nm was as high as 0.48 on average for 17 breast cancer patients with respect to the polypeptide.
- Example 2 using the canine CAPRIN-1 polypeptide (SEQ ID NO: 8) prepared in Example 2 and an anti-human IgG antibody, an IgG antibody in human serum that specifically reacts with the polypeptide in the same manner as described above. The value was measured. As a result, the average of 7 healthy people was 0.04, whereas the average of 17 breast cancer patients was as high as 0.55.
- Example 5 Cancer diagnosis by measuring antigen polypeptide Polyclonal antibody against CAPRIN-1-derived peptide (SEQ ID NO: 43) obtained in Example 3 (1) and CAPRIN- obtained in Example 3 (2) Specimens that gave a positive reaction in cancer diagnosis using the CAPRIN-1 polypeptide in Examples 4 (1) to (3) by sandwich ELISA using a combination of monoclonal antibodies against one protein (both The antigen polypeptide itself contained in the serum of the cancer individual was detected. A polyclonal antibody was used as the primary antibody, and each monoclonal antibody was used as the secondary antibody. The amount of the protein in serum that specifically reacts with each of the above antibodies was measured.
- any sample of a cancer-bearing dog such as breast cancer or malignant melanoma or a tumor-bearing cat Absorbance values (polypeptide values) of 0.3 or more were detected, but not in healthy dogs and healthy cats.
- the absorbance value was detected in all specimens although the polypeptide value was detected. All were 0.05 or less, and were low values compared with the combination of the antibodies reacting on the cell surface of the cancer cells.
- cancer could also be diagnosed by this technique of detecting an antigen polypeptide using an antibody against CAPRIN-1.
- the present invention is industrially useful for cancer diagnosis or detection.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
(1)cDNAライブラリーの作製
健常な犬の精巣組織から酸グアニジウム-フェノール-クロロホルム法(Acid guanidium-Phenol-Chloroform法)により全RNAを抽出し、Oligotex-dT30 mRNA purification Kit(宝酒造社製)を用いてキット添付のプロトコールに従ってポリA RNAを精製した。
上記作製したイヌ精巣cDNAファージライブラリーを用いて、イムノスクリーニングを行った。具体的にはΦ90×15mmのNZYアガロースプレートに2210クローンとなるように宿主大腸菌(XL1-Blue MRF’)に感染させ、42℃、3~4時間培養し、溶菌斑(プラーク)を作らせ、IPTG(イソプロピル-β-D-チオガラクトシド)を浸透させたニトロセルロースメンブレン(Hybond C Extra: GE Healthecare Bio-Science社製)でプレートを37℃で4時間覆うことによりタンパク質を誘導・発現させ、メンブレンにタンパク質を転写した。その後メンブレンを回収し0.5%脱脂粉乳を含むTBS(10mM Tris-HCl、150mM NaCl pH7.5)に浸し4℃で一晩振盪することによって非特異反応を抑制した。このフィルターを500倍希釈した患犬血清と室温で2~3時間反応させた。
上記方法により単離した5個の陽性クローンを塩基配列解析に供するため、ファージベクターからプラスミドベクターに転換する操作を行った。具体的には宿主大腸菌(XL1-Blue MRF’)を吸光度OD600が1.0となるよう調製した溶液200μlと、精製したファージ溶液250μlさらにExAssist helper phage (STRATAGENE社製)1μlを混合した後37℃で15分間反応後、LB培地を3ml添加し37℃で2.5~3時間培養を行い、直ちに70℃の水浴にて20分間保温した後、4℃、1000×g、15分間遠心を行い、上清をファージミド溶液として回収した。次いでファージミド宿主大腸菌(SOLR)を吸光度OD600が1.0となるよう調製した溶液200μlと、精製したファージ溶液10μlを混合した後37℃で15分間反応させ、50μlをアンピシリン(終濃度50μg/ml)含有LB寒天培地に播き37℃一晩培養した。トランスフォームしたSOLRのシングルコロニーを採取し、アンピシリン(終濃度50μg/ml)含有LB培地37℃にて培養後、QIAGEN plasmid Miniprep Kit(キアゲン社製)を使って目的のインサートを持つプラスミドDNAを精製した。
上記方法により得られた遺伝子に対しイヌ及びヒトの正常組織及び各種細胞株における発現をRT-PCR(Reverse Transcription-PCR)法により調べた。逆転写反応は以下の通り行なった。すなわち、各組織50~100mg及び各細胞株5~10×106個の細胞からTRIZOL試薬(invitrogen社製)を用いて添付のプロトコールに従い全RNAを抽出した。この全RNAを用いてSuperscript First-Strand Synthesis System for RT-PCR(invitrogen社製)により添付のプロトコールに従いcDNAを合成した。PCR反応は、取得した遺伝子特異的なプライマー(配列番号33及び34に記載)を用いて以下の通り行った。すなわち、逆転写反応により調製したサンプル0.25μl、上記プライマーを各2μM、0.2mM各dNTP、0.65UのExTaqポリメラーゼ(宝酒造社製)となるように各試薬と添付バッファーを加え全量を25μlとし、Thermal Cycler(BIO RAD社製)を用いて、94℃/30秒、60℃/30秒、72℃/30秒のサイクルを30回繰り返して行った。なお、上記遺伝子特異的プライマーは、配列番号5の塩基配列(イヌCAPRIN-1遺伝子)中の206番~632番及び配列番号1の塩基配列(ヒトCAPRIN-1遺伝子)中の698番~1124番塩基の領域を増幅するものであった。比較対照のため、GAPDH特異的なプライマー(配列番号35及び36に記載)も同時に用いた。その結果、図1に示すように、健常なイヌ組織では精巣に強い発現が見られ、一方イヌ乳癌及び腺癌組織で発現が見られた。さらに、取得した遺伝子のヒト相同因子の発現を併せて確認したところ、イヌCAPRIN-1遺伝子と同様、正常組織で発現が確認できたのは精巣のみだったが、癌細胞では乳癌、脳腫瘍、白血病、肺癌、食道癌細胞株など、多種類の癌細胞株で発現が検出され、特に多くの乳癌細胞株で発現が確認された。この結果から、CAPRIN-1は精巣以外の正常組織では発現が見られず、一方、多くの癌細胞で発現しており、特に乳癌細胞株に発現していることが確認された。
(5)-1 マウスおよびイヌ正常組織におけるCAPRIN-1の発現
マウス(Balb/c、雌)およびイヌ(ビーグル犬、雌)をエーテル麻酔下およびケタミン/イソフルラン麻酔下で放血させ、開腹後、各臓器(胃、肝臓、眼球、胸腺、筋肉、骨髄、子宮、小腸、食道、心臓、腎臓、唾液腺、大腸、乳腺、脳、肺、皮膚、副腎、卵巣、膵臓、脾臓、膀胱)をそれぞれPBSの入った10cmディッシュに移した。PBS中で各臓器を切り開き、4%paraformaldehyde(PFA)を含む0.1Mリン酸緩衝液(pH7.4)で一晩還流固定した。還流液を捨て、PBSで各臓器の組織表面をすすぎ、10%ショ糖を含むPBS溶液を50ml容の遠心チューブに入れ、その中に各組織を入れて4℃で2時間ローターを用いて振とうした。20%ショ糖を含むPBS溶液に入れ替え、4℃で組織が沈むまで静置後、30%ショ糖を含むPBS溶液に入れ替え、4℃で組織が沈むまで静置した。組織を取り出し、必要な部分を手術用メスで切りだした。次に、OCTコンパウンド(Tissue Tek社製)をかけて組織表面になじませた後、クライオモルドに組織を配置した。ドライアイスの上にクライオモルドをおいて急速凍結させた後、クライオスタット(LEICA社製)を用いて10~20μmに薄切し、スライドガラスごとヘアードライアーで30分間風乾し、薄切組織がのったスライドガラス作製した。次にPBS-T(0.05% Tween20を含む生理食塩水)を満たした染色瓶に入れて5分ごとにPBS-Tを入れ替える操作を3回行った。切片周囲の余分な水分をキムワイプでふき取り、DAKOPEN(DAKO社製)で囲んだ後、ブロッキング液として、マウス組織はMOMマウスIgブロッキング試薬(VECTASTAIN社製)を、イヌ組織は10%牛胎児血清を含むPBS-T溶液をそれぞれのせ、モイストチャンバー上で室温で1時間静置した。次に実施例3で作製した癌細胞表面に反応する、配列番号:55の重鎖可変領域と配列番号:56の軽鎖可変領域を有するCAPRIN-1に対するモノクローナル抗体(モノクローナル抗体#8)をブロッキング液で10μg/mlに調製した溶液をのせ、モイストチャンバー内で4℃下で一晩静置した。PBS-Tで10分間3回洗浄を行った後、ブロッキング液で250倍に希釈したMOMビオチン標識抗IgG抗体(VECTASTAIN社製)をのせ、モイストチャンバー内に室温で1時間静置した。PBS-Tで10分間3回洗浄を行った後、アビジンービオチンABC試薬(VECTASTAIN社製)をのせ、モイストチャンバー内で室温で5分間静置した。PBS-Tで10分間3回洗浄を行った後、DAB発色液(DAB 10mg+30% H2O2 10μl/0.05M Tris-HCl(pH7.6)50ml)をのせ、モイストチャンバー内に室温で30分間静置した。蒸留水でリンスし、ヘマトキシリン試薬(DAKO社製)を載せて室温で1分間静置後、蒸留水でリンスした。70%、80%、90%、95%、100%の各エタノール溶液に順番に1分間ずつ入れた後、キシレン中で一晩静置した。スライドガラスを取り出し、Glycergel Mounting Medium(DAKO社製)で封入後、観察を行った。その結果、CAPRIN-1は、唾液腺、腎臓、結腸、胃の各組織において細胞内で僅かに発現が認められたが、細胞表面での発現は認められず、また、その他の臓器由来の組織では全く発現が認められなかった。
病理診断で悪性乳癌と診断されたイヌの凍結された乳癌組織108検体を用いて、上述と同様の方法で凍結切片スライド作製および実施例3で作製したモノクローナル抗体#8を用いた免疫組織化学染色を行った。その結果、CAPRIN-1は108検体中100検体(92.5%)で発現が確認され、特に異型度の高い癌細胞表面に強く発現していた。
パラフィン包埋されたヒト乳癌組織アレイ(BIOMAX社製)の乳癌組織188検体を用いて、免疫組織化学染色を行った。ヒト乳癌組織アレイを60℃で3時間処理後、キシレンを満たした染色瓶に入れて5分ごとにキシレンを入れ替える操作を3回行った。次にキシレンの代わりにエタノールおよびPBS-Tで同様の操作を行った。0.05% Tween20を含む10mM クエン酸緩衝液(pH6.0)を満たした染色瓶にヒト乳癌組織アレイを入れ、125℃で5分間処理後、室温で40分以上静置した。切片周囲の余分な水分をキムワイプでふき取り、DAKOPEN(DAKO社製)で囲み、Peroxidase Block(DAKO社製)を適量滴下した。室温で5分間静置後、PBS-Tを満たした染色瓶に入れて5分ごとにPBS-Tを入れ替える操作を3回行った。ブロッキング液として、10% FBSを含むPBS-T溶液をのせ、モイストチャンバー内で室温で1時間静置した。次に実施例3で作製したモノクローナル抗体#8を5% FBSを含むPBS-T溶液で10μg/mlに調製した溶液をのせ、モイストチャンバー内に4℃で一晩静置した。PBS-Tで10分間3回洗浄を行った後、Peroxidase Labelled Polymer Conjugated(DAKO社製)適量滴下し、モイストチャンバー内で室温で30分間静置した。PBS-Tで10分間3回洗浄を行った後、DAB発色液(DAKO社製)をのせ、室温で10分程度静置した後、発色液を捨て、PBS-Tで10分間3回洗浄を行った後、蒸留水でリンスし、70%、80%、90%、95%、100%の各エタノール溶液に順番に1分間ずつ入れた後、キシレン中で一晩静置した。スライドガラスを取り出し、Glycergel Mounting Medium(DAKO社製)で封入後、観察を行った。その結果、CAPRIN-1は全乳癌組織188検体の内、138検体(73%)で強い発現が認められた。
パラフィン包埋されたヒト悪性脳腫瘍組織アレイ(BIOMAX社製)の悪性脳腫瘍組織247検体を用いて、上述(5)-3と同様の方法で実施例3で作製したモノクローナル抗体#8を用いた免疫組織化学染色を行った。その結果、CAPRIN-1は全悪性脳腫瘍組織247検体の内、227検体(92%)で強い発現が認められた。
パラフィン包埋されたヒト乳癌転移リンパ節組織アレイ(BIOMAX社製)の乳癌転移リンパ節組織150検体を用いて、上述(5)-3と同様の方法で実施例3で作製したモノクローナル抗体#8を用いた免疫組織化学染色を行った。その結果、CAPRIN-1は全乳癌転移リンパ節組織150検体の内、136検体(90%)で強い発現が認められた。すなわち、乳癌から転移した癌組織においてもCAPRIN-1は強く発現することが判った。
(1)組換えタンパク質の作製
実施例1で取得した配列番号5の遺伝子を基に、以下の方法にて組換えタンパク質を作製した。PCRは、実施例1で得られたファージミド溶液より調製し配列解析に供したベクターを1μl、NdeI及びKpnI制限酵素切断配列を含む2種類のプライマー(配列番号37及び38に記載)を各0.4μM、0.2mM dNTP、1.25UのPrimeSTAR HSポリメラーゼ(宝酒造社製)となるように各試薬と添付バッファーを加え全量を50μlとし、Thermal Cycler (BIO RAD社製)を用いて、98℃/10秒、68℃/1.5分のサイクルを30回繰り返すことにより行った。なお、上記2種類のプライマーは、配列番号6(P47)のアミノ酸配列全長をコードする領域を増幅するものであった。PCR後、増幅されたDNAを1%アガロースゲルにて電気泳動し、QIAquick Gel Extraction Kit (QIAGEN社製)を用いて約1.4kbpのDNA断片を精製した。
上記で得られた、配列番号1,5,7の遺伝子を発現するそれぞれの組換え大腸菌を30μg/ml カナマイシン含有LB培地にて600nmでの吸光度が0.7付近になるまで37℃で培養後、イソプロピル-β-D-1-チオガラクトピラノシド終濃度が1mMとなるよう添加し、37℃で4時間培養した。その後4800rpmで10分間遠心し集菌した。この菌体ペレットをリン酸緩衝化生理食塩水に懸濁し、さらに4800rpmで10分間遠心し菌体の洗浄を行った。
(1)CAPRIN-1由来ペプチドに対するポリクローナル抗体の作製
CAPRIN-1に結合する抗体を得るために、CAPRIN-1由来ペプチド(Arg-Asn-Leu-Glu-Lys-Lys-Lys-Gly-Lys-Leu-Asp-Asp-Tyr-Gln(配列番号43))を合成した。このペプチド1mgを抗原として、等容量の不完全フロイントアジュバント(IFA)溶液と混合し、これを2週間毎に4回、ウサギの皮下に投与を行った。その後血液を採取し、ポリクローナル抗体を含む抗血清を得た。さらにこの抗血清をプロテインG担体(GEヘルスケアバイオサイエンス社製)を用いて精製し、CAPRIN-1由来ペプチドに対するポリクローナル抗体を得た。次に得られたポリクローナル抗体の乳癌細胞表面に対する反応性を検討した。具体的には、106個のヒト乳癌細胞株MDA-MB-231Vを1.5ml容のミクロ遠心チューブにて遠心分離し、これに上記ポリクローナル抗体を含む0.1%牛胎児血清(FBS)入りPBS溶液を添加し、氷上で1時間静置した。PBSで洗浄した後、0.1%FBSを含むPBSで500倍希釈したFITC標識ヤギ抗マウスIgG抗体(インビトロジェン社製)を添加し、氷上で1時間静置した。PBSで洗浄後、ベクトンディッキンソン株式会社のFACSキャリバーにて蛍光強度を測定した。一方、上記と同様の操作を、ポリクローナル抗体の代わりに0.1% FBSを含むPBSを添加したものをコントロールとした。その結果、ポリクローナル抗体を処理した細胞は、コントロールの細胞に比べて蛍光強度が強く、従って、得られたポリクローナル抗体が乳癌細胞の細胞表面に結合するものであることが判った。
実施例2で調製した配列番号2に示される、抗原タンパク(ヒトCAPRIN-1)100μgを等量のMPL+TDMアジュバント(シグマ社製)と混合し、これをマウス1匹当たりの抗原溶液とした。抗原溶液を6週齢のBalb/cマウス(日本SLC社製)の腹腔内に投与後、1週間毎にさらに3回投与を行った。最後の免疫から3日後に摘出した脾臓を滅菌した2枚のスライドガラスに挟んで擦り潰し、PBS(-)(日水社製)を用いて洗浄し1500rpmで10分間遠心して上清を除去する操作を3回繰り返して脾臓細胞を得た。得られた脾臓細胞とマウスミエローマ細胞SP2/0(ATCCから購入)とを10:1の比率にて混和し、そこに37℃に加温した10%FBSを含むRPMI1640培地200μlとPEG1500(ベーリンガー社製)800μlを混和して調製したPEG溶液を加えて5分間静置して細胞融合を行った。1700rpmで5分間遠心し、上清を除去後、ギブコ社製のHAT溶液を2%当量加えた15% FBSを含むRPMI1640培地(HAT選択培地)150mlで細胞を懸濁し、96穴プレート(ヌンク社製)の1ウェル当たり100μlずつ、プレート15枚に播種した。7日間、37℃、5%CO2の条件で培養することで、脾臓細胞とミエローマ細胞が融合したハイブリドーマを得た。
上記で取得した、癌細胞の細胞表面に反応する#1~#10のCAPRIN-1に対するモノクローナル抗体を用いて、それらが認識するCAPRIN-1タンパク質中の部分配列の同定を行った。
(1)イヌの癌診断
悪性又は良性腫瘍の確認された患犬342頭と健常犬6頭の血液を採取し、血清を分離した。実施例2で作製したイヌCAPRIN-1のポリペプチド(配列番号8)、抗イヌIgG抗体を用いてELISA法にて該ポリペプチドに特異的に反応する血清中のIgG抗体価を測定した。
患犬1(フラットコーテットレトリバー)は、2007年6月7日時点で腫瘤が確認されていなかったが、その20日ほど後の2007年6月24日に左上顎犬歯の付け根の歯肉に有茎状の直径2mmの腫瘤が発見された患犬である。発見された日に有茎部を結糸し、切除を行っている。肉眼で腫瘤を確認できる以前の450nmでの吸光度は0.06であり、腫瘍発見時0.04と比較しても大きく変わらなかった。この結果から本手法を用いることにより、腹腔内など目に見えない部分の癌診断でも可能なことがわかった。
癌の進行度は腫瘍の大きさや深さ、周辺組織にどれほど影響を及ぼしているか、転移をしているかなどによって判断される。転移すなわち癌が進行すると以前より高い値が検出されることがわかった。
基底細胞腫には悪性型と良性型とがあり、近年、新WHOでは悪性型を基底細胞癌、良性型を毛芽腫と分類するという傾向にあるとのことである。
患犬6(雑種)は、肥満細胞腫で来院し2005年5月23日に摘出手術を行っている。この際行った血清診断の結果、450nmでの吸光度は0.10であった。肥満細胞腫は完全に採りきれていない場合、再発や転移を繰り返す腫瘍のため、手術により腫瘍の完全切除ができたか否かということは、重要である。2006年12月19日の経過観察の際には、450nmでの吸光度は0.05と抗体価の低下が確認された。このとき再発は確認されていない。よって患犬6では、完全に腫瘍を切除できたために血清診断結果は手術時よりも低下したといえる。
患犬8(ハスキー)は、2007年5月8日に乳腺癌の摘出手術を行っている。この際行った血清診断の結果、450nmでの吸光度は0.05であった。摘出した組織を用いた病理診断では、異型性の強い上皮系細胞が主に腺管構造を形成、増殖しており乳腺原発の腺癌と診断された。そのとき既にリンパ管内に多数の癌細胞が入っているのが確認されており、リンパ節や遠隔部への転移、再発のリスクが高いということであった。手術から約一ヶ月半後の2007年6月28日に同部位に再発が確認された。このときの血清診断の結果は0.09と値の上昇が確認された。患犬8では、腫瘍が切除しきれていなかったか又は、再発したために、診断結果が5月初旬よりも6月下旬のほうが大きく検出されたとわかった。
患犬9(スコティッシュテリア)は、2003年2月 乳腺腫瘍、2003年8月 口腔内悪性黒色腫、2005年1月 口唇に悪性黒色腫、2005年4月13日 口腔内黒色腫と転移・再発を繰り返し、これらすべて手術で切除済みの患犬である。2005年4月の口腔内黒色腫の再発の後に、経過観察で再来院した2006年12月17日の血清診断の結果は、450nmでの吸光度が0.09であった。その半年後の2007年6月20日には頚部リンパ、膝きょうリンパが肥大して再来院している。リンパ腫であれば全身のリンパが腫れるが、患犬9については2箇所のみであったため、おそらく転移によるリンパ腫である可能性が高いとの臨床診断であった。本手法による診断によっても、450nmでの吸光度は0.10と上昇しており、以前存在した腫瘍の転移であることがわかった。
実施例2で作製したヒトCAPRIN-1のポリペプチド(配列番号2)を用いて、上記と同様にして、該ポリペプチドに反応する、イヌ血清中のIgG抗体価を測定した。健常犬血清を用いた検討結果では、上記と同様に450nmでの吸光度はほとんど検出されなかった。
次に担癌猫及び健常猫の診断を行った。上記で用いたイヌCAPRIN-1のポリペプチドと抗ネコIgG抗体を用いて、上記と同様にして、該ポリペプチドに特異的に反応するネコ血清中のIgG抗体価を測定した。2次抗体は、HRP修飾抗ネコIgG抗体(PEROXIDASE-CONJUGATED GOAT IgG FRACTION TO CAT IgG (WHOLE MOLECULE): CAPPEL RESERCH REAGENTS社製)をブロッキング溶液にて8000倍希釈して用いた。
実施例2で作製したヒトCAPRIN-1のポリペプチド(配列番号2)と抗ヒトIgG抗体を用いて、該ポリペプチドに特異的に反応する健常人血清中のIgG抗体価を測定した。作製したポリペプチドの固相化は、リン酸緩衝化生理食塩水にて100μg/mLに希釈した組換えタンパク質溶液を96穴イモビライザーアミノプレート(ヌンク社製)に100μl/well添加し、4℃で一晩静置して行った。ブロッキングは、ブロックエース粉末(DSファ-マバイオメディカル株式会社製)4gを精製水100mlに溶解した溶液を精製水で4倍希釈したもの(以下ブロッキング溶液)を100μl/well加え、室温で1時間振とうした。希釈にブロッキング溶液を用いた1000倍希釈血清を100μl/well添加し、室温で3時間振とうして反応させた。0.05%Tween20(和光純薬工業社製)含有リン酸緩衝化生理食塩水(以下PBS-T)で3回洗浄し、ブロッキング溶液にて10000倍希釈したHRP修飾抗ヒトIgG抗体(HRP-Goat Anti-Human IgG(H+L) Conjugate: Zymed Laboratories社製)を100μl/well加え、室温で1時間振とうして反応させた。PBS-Tで3回洗浄し、HRP基質 TMB(1-Step Turbo TMB(テトラメチルベンジジン)、PIERCE社)を100μl/well添加し、室温で30分間酵素基質反応させた。その後、0.5M硫酸溶液(シグマアルドリッチジャパン社製)を100μl/well加えて反応停止後、マイクロプレートリーダーにて450nmの吸光度測定を行った。ポジティブコントロールとしてリン酸緩衝化生理食塩水にて50μg/mlに調製した卵白アルブミン抗原を固相化したものを用いた。その結果、450nmでの吸光度は、卵白アルブミン抗原に対して健常人7人の平均で0.45と高い値を示した。一方、上記ポリペプチドに対しては0と全く検出されなかった。
実施例3(1)で取得した、CAPRIN-1由来ペプチド(配列番号43)に対するポリクローナル抗体と実施例3(2)で取得した、CAPRIN-1タンパクに対する各モノクローナル抗体を組み合わせて用いることによる、サンドイッチELISA法により、実施例4(1)~(3)においてCAPRIN-1のポリペプチドを用いた癌診断で陽性反応が得られた検体(担癌個体由来血清)中に含まれる該抗原ポリペプチド自体の検出を行った。1次抗体としてポリクローナル抗体を、2次抗体として各モノクローナル抗体を用いた。上記各抗体に特異的に反応する、血清中の該タンパク量を測定した。
Claims (22)
- 生体から分離された試料において、配列表の配列番号2~30のうち偶数の配列番号に示されるいずれかのアミノ酸配列を有するCAPRIN-1タンパク質に対する抗体と抗原抗体反応により結合する反応性を有するポリペプチドの発現を測定することを含む、癌の検出方法。
- 測定すべき前記ポリペプチドは、配列番号2~30のうち偶数の配列番号に示されるいずれかのアミノ酸配列を有するCAPRIN-1タンパク質、又は該CAPRIN-1タンパク質と85%以上の配列同一性を有するポリペプチドである、請求項1記載の方法。
- 前記生体が、ヒト、イヌ又はネコである、請求項1又は2記載の方法。
- 前記生体がイヌであり、測定すべき前記ポリペプチドは配列番号2~30のうち偶数の配列番号に示されるいずれかのアミノ酸配列を有する、請求項3記載の方法。
- 前記生体がイヌであり、測定すべき前記ポリペプチドは配列番号6、8、10、12又は14に示されるアミノ酸配列を有する、請求項4記載の方法。
- 前記生体がヒトであり、測定すべき前記ポリペプチドは配列番号2又は4に示されるアミノ酸配列を有する、請求項3記載の方法。
- 前記ポリペプチドの発現の測定は、前記試料に含まれ得る、測定すべき前記ポリペプチドに対し前記生体内で誘導された抗体を免疫測定することにより行われる請求項1~6のいずれか1項に記載の方法。
- 前記試料が、血清、血漿、腹水又は胸水である、請求項1~7のいずれか1項に記載の方法。
- 前記ポリペプチドの発現の測定は、前記試料中に含まれる、該ポリペプチドをコードするmRNAを測定することにより行われる、請求項1~6のいずれか1項に記載の方法。
- 前記mRNAの塩基配列中の15塩基以上の部分配列と特異的にハイブリダイズするポリヌクレオチドを用いて、前記試料中の前記mRNAの存在量を調べる、請求項9記載の方法。
- 前記生体がイヌであり、前記ポリヌクレオチドは配列番号5、7、9、11又は13に示される塩基配列中の15塩基以上の部分配列と特異的にハイブリダイズするポリヌクレオチドである、請求項10記載の方法。
- 前記生体がヒトであり、前記ポリヌクレオチドは配列番号1又は3に示される塩基配列中の15塩基以上の部分配列と特異的にハイブリダイズするポリヌクレオチドである、請求項10記載の方法。
- 前記試料が組織又は細胞である、請求項9~12のいずれか1項に記載の方法。
- 前記癌が、脳腫瘍、頭、首、肺、子宮、又は食道の扁平上皮癌、メラノーマ、肺又は子宮の腺癌、腎癌、悪性混合腫瘍、肝細胞癌、基底細胞癌、勅細胞腫様歯肉腫、口腔内腫瘤、肛門周囲腺癌、肛門嚢腫瘤、肛門嚢アポクリン腺癌、セルトリ細胞腫、膣前庭癌、皮脂腺癌、皮脂腺上皮腫、脂腺腺腫、汗腺癌、鼻腔内腺癌、鼻腺癌、甲状腺癌、大腸癌、気管支腺癌、腺癌、腺管癌、乳腺癌、複合型乳腺癌、乳腺悪性混合腫瘍、乳管内乳頭状腺癌、線維肉腫、血管周皮腫、骨肉腫、軟骨肉腫、軟部組織肉腫、組織球肉腫、粘液肉腫、未分化肉腫、肺癌、肥満細胞腫、皮膚平滑筋腫、腹腔内平滑筋腫、平滑筋腫、慢性型リンパ球性白血病、リンパ腫、消化管型リンパ腫、消化器型リンパ腫、小~中細胞型リンパ腫、副腎髄質腫瘍、顆粒膜細胞腫及び褐色細胞腫からなる群より選ばれる少なくとも1種の癌である、請求項1~13のいずれか1項に記載の方法。
- 前記ポリペプチドの発現量が対照と比べて多い場合に癌の悪性度が高くなることに基づき、癌の悪性度をさらに検出することを含む、請求項1~14のいずれか1項に記載の方法。
- 前記ポリペプチドの発現量が対照と比べて多い場合に癌の進行度が進んでいることに基づき、癌の進行度をさらに検出することを含む、請求項1~15のいずれか1項に記載の方法。
- 配列表の配列番号2~30のうち偶数の配列番号に示されるいずれかのアミノ酸配列を有するCAPRIN-1タンパク質に対して生体内で誘導される抗体と抗原抗体反応により結合する反応性を有するポリペプチドを含む癌検出試薬。
- 配列表の配列番号2~30のうち偶数の配列番号に示されるいずれかのアミノ酸配列を有するCAPRIN-1タンパク質に対する抗体と抗原抗体反応により結合する反応性を有し生体内で産生されるポリペプチドと抗原抗体反応する抗体又はその抗原結合性断片を含む癌検出試薬。
- 前記ポリペプチドと抗原抗体反応する抗体又はその抗原結合性断片が、癌細胞の表面に結合する抗体又はその抗原結合性断片である、請求項18記載の癌検出試薬。
- 前記ポリペプチドと抗原抗体反応する抗体又はその抗原結合性断片が、配列番号2~30のうち配列番号6および配列番号18を除く偶数の配列番号で表されるいずれかのアミノ酸配列中のアミノ酸残基番号50-98又はアミノ酸残基番号233-305の領域内の連続する7個以上のアミノ酸配列からなるポリペプチド、又は該ポリペプチドを部分配列として含むポリペプチド、と免疫学的反応性を有する抗体又はそのフラグメントを含むことを特徴とする、請求項18又は19記載の癌検出試薬。
- 前記ポリペプチドと抗原抗体反応する抗体又はその抗原結合性断片が、配列番号43に結合する抗体又はその抗原結合性断片、配列番号44と45のアミノ酸配列を有するモノクローナル抗体又はその抗原結合性断片、配列番号44と46のアミノ酸配列を有するモノクローナル抗体又はその抗原結合性断片、配列番号44と47のアミノ酸配列を有するモノクローナル抗体又はその抗原結合性断片、配列番号44と48のアミノ酸配列を有するモノクローナル抗体又はその抗原結合性断片、配列番号49と50のアミノ酸配列を有するモノクローナル抗体又はその抗原結合性断片、配列番号51と52のアミノ酸配列を有するモノクローナル抗体又はその抗原結合性断片、配列番号53と54のアミノ酸配列を有するモノクローナル抗体又はその抗原結合性断片、配列番号55と56のアミノ酸配列を有するモノクローナル抗体又はその抗原結合性断片、配列番号57と58のアミノ酸配列を有するモノクローナル抗体又はその抗原結合性断片、あるいは配列番号59と60のアミノ酸配列を有するモノクローナル抗体又はその抗原結合性断片である、請求項18~20のいずれか1項に記載の癌検出試薬。
- 配列表の配列番号1~29のうち奇数の配列番号に示されるいずれかの塩基配列中の15塩基以上の部分配列と特異的にハイブリダイズするポリヌクレオチドを含む癌検出試薬。
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0911925A BRPI0911925B8 (pt) | 2008-08-05 | 2009-08-05 | Método para detectar um câncer |
RU2011108258/15A RU2519089C2 (ru) | 2008-08-05 | 2009-08-05 | Способ обнаружения злокачественных опухолей |
MX2011001445A MX2011001445A (es) | 2008-08-05 | 2009-08-05 | Metodo para detectar cancer. |
KR1020167007417A KR20160039295A (ko) | 2008-08-05 | 2009-08-05 | 암의 검출 방법 |
JP2009546599A JP5644110B2 (ja) | 2008-08-05 | 2009-08-05 | 癌の検出方法 |
DK09805010.7T DK2325648T3 (da) | 2008-08-05 | 2009-08-05 | Fremgangsmåde til detektering af cancer |
EP09805010.7A EP2325648B1 (en) | 2008-08-05 | 2009-08-05 | Method for detecting cancer |
PL09805010T PL2325648T3 (pl) | 2008-08-05 | 2009-08-05 | Sposób wykrywania nowotworów |
KR1020117004614A KR101606779B1 (ko) | 2008-08-05 | 2009-08-05 | 암의 검출 방법 |
CN200980139037.XA CN102171570B (zh) | 2008-08-05 | 2009-08-05 | 用于检测癌的方法 |
US13/057,515 US11137401B2 (en) | 2008-08-05 | 2009-08-05 | Method for detecting cancer using CAPRIN-1 as a marker |
AU2009278387A AU2009278387B2 (en) | 2008-08-05 | 2009-08-05 | Cancer detection method |
CA2732980A CA2732980C (en) | 2008-08-05 | 2009-08-05 | Caprin-1 as a target for diagnosing cancer |
MX2013011525A MX337991B (es) | 2008-08-05 | 2009-08-05 | Metodo para detectar cancer. |
ES09805010.7T ES2471379T3 (es) | 2008-08-05 | 2009-08-05 | Método para detectar el cáncer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008202320 | 2008-08-05 | ||
JP2008-202320 | 2008-08-05 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14153299.4A Previously-Filed-Application EP2733492B1 (en) | 2008-08-05 | 2009-08-05 | Cancer detection method |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010016527A1 true WO2010016527A1 (ja) | 2010-02-11 |
Family
ID=41663744
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/063883 WO2010016527A1 (ja) | 2008-08-05 | 2009-08-05 | 癌の検出方法 |
Country Status (16)
Country | Link |
---|---|
US (1) | US11137401B2 (ja) |
EP (2) | EP2325648B1 (ja) |
JP (2) | JP5644110B2 (ja) |
KR (2) | KR101606779B1 (ja) |
CN (1) | CN102171570B (ja) |
AU (2) | AU2009278387B2 (ja) |
BR (1) | BRPI0911925B8 (ja) |
CA (1) | CA2732980C (ja) |
DK (2) | DK2733492T3 (ja) |
ES (2) | ES2570731T3 (ja) |
HU (1) | HUE027332T2 (ja) |
MX (2) | MX2011001445A (ja) |
PL (2) | PL2733492T3 (ja) |
PT (1) | PT2325648E (ja) |
RU (2) | RU2519089C2 (ja) |
WO (1) | WO2010016527A1 (ja) |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011096517A1 (ja) * | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2011096535A1 (ja) * | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
WO2011096533A1 (ja) * | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2011096528A1 (ja) * | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2011096519A1 (ja) * | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
EP2532743A1 (en) * | 2010-02-04 | 2012-12-12 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
WO2013018894A1 (ja) * | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2013018891A1 (ja) * | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2013018883A1 (ja) * | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2013018885A1 (ja) * | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 膵臓癌の検出方法 |
WO2013018892A1 (ja) * | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2013018889A1 (ja) * | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2013125630A1 (ja) * | 2012-02-21 | 2013-08-29 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2013125636A1 (ja) * | 2012-02-21 | 2013-08-29 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2013125654A1 (ja) * | 2012-02-21 | 2013-08-29 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2013125640A1 (ja) * | 2012-02-21 | 2013-08-29 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2013147176A1 (ja) * | 2012-03-30 | 2013-10-03 | 東レ株式会社 | 胆嚢癌の治療及び/又は予防用医薬組成物 |
WO2013147169A1 (ja) * | 2012-03-30 | 2013-10-03 | 東レ株式会社 | 肝臓癌の治療及び/又は予防用医薬組成物 |
WO2014014082A1 (ja) | 2012-07-19 | 2014-01-23 | 東レ株式会社 | 癌の検出方法 |
WO2014014086A1 (ja) | 2012-07-19 | 2014-01-23 | 東レ株式会社 | 癌の検出方法 |
EP2740489A4 (en) * | 2011-08-04 | 2015-03-04 | Toray Industries | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF PANCREATIC CARCINOMA |
US9416192B2 (en) | 2008-08-05 | 2016-08-16 | Toray Industries, Inc. | Pharmaceutical composition for treatment and prevention of cancers |
RU2611896C1 (ru) * | 2016-03-10 | 2017-03-01 | Федеральное государственное бюджетное учреждение здравоохранения Клиническая больница N 122 имени Л.Г. Соколова Федерального медико-биологического агентства (ФГБУЗ КБ N 122 им. Л.Г. Соколова ФМБА России) | Способ диагностики лейомиомы мочевого пузыря |
US9862774B2 (en) | 2013-08-09 | 2018-01-09 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
CN110573618A (zh) * | 2017-03-30 | 2019-12-13 | 第一三共株式会社 | 抗gpr20抗体 |
US11137401B2 (en) | 2008-08-05 | 2021-10-05 | Toray Industries, Inc. | Method for detecting cancer using CAPRIN-1 as a marker |
RU2812681C1 (ru) * | 2023-03-27 | 2024-01-31 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ определения предрасположенности к развитию рака щитовидной железы |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6737504B2 (ja) * | 2014-11-27 | 2020-08-12 | 公立大学法人横浜市立大学 | 卵巣明細胞腺癌の検査方法及び検査薬 |
EP3606962A4 (en) * | 2017-04-04 | 2020-12-23 | Corvus Pharmaceuticals, Inc. | TREATMENT METHODS FOR HIGH CD73 TUMORS |
RU2677064C1 (ru) * | 2017-10-13 | 2019-01-15 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ определения границ резекции при лечении остеосаркомы |
WO2020067261A1 (ja) * | 2018-09-26 | 2020-04-02 | 株式会社レナテック | 犬のがんリスク評価方法及びがんリスク評価システム |
JP6875451B2 (ja) * | 2018-09-26 | 2021-05-26 | 株式会社レナテック | 犬のがんリスク評価方法及びがんリスク評価システム |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002540790A (ja) * | 1999-04-02 | 2002-12-03 | コリクサ コーポレイション | 肺癌の治療および診断のための化合物ならびにその使用のための方法 |
JP2003528587A (ja) * | 1999-10-29 | 2003-09-30 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 27個のヒト分泌タンパク質 |
WO2005100998A2 (en) | 2004-04-16 | 2005-10-27 | Europroteome Ag | Membrane markers for use in cancer diagnosis and therapy |
US20080075722A1 (en) | 2006-02-14 | 2008-03-27 | Depinho Ronald A | Compostions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
WO2008088583A2 (en) * | 2006-08-30 | 2008-07-24 | Immunotope, Inc | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
JP2008202320A (ja) | 2007-02-21 | 2008-09-04 | Kajima Corp | シールド機、シールド機とセグメントの間のクリアランス測定方法 |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9102074D0 (sv) | 1991-07-03 | 1991-07-03 | Kabi Pharmacia Ab | Tomour antigen specific antibody |
DK0782709T3 (da) | 1994-09-19 | 2010-03-29 | Ricardo J Moro | Detektering af cancer |
US5698396A (en) * | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
US20030118599A1 (en) * | 1999-04-02 | 2003-06-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
RU2234942C2 (ru) | 1998-07-14 | 2004-08-27 | Корикса Корпорейшн | Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид |
HUP0203035A3 (en) | 1998-07-14 | 2007-12-28 | Corixa Corp | Compositions and methods for therapy and diagnosis of prostate cancer |
GB9815909D0 (en) | 1998-07-21 | 1998-09-16 | Btg Int Ltd | Antibody preparation |
US6969518B2 (en) * | 1998-12-28 | 2005-11-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
US6335170B1 (en) * | 1999-02-22 | 2002-01-01 | Torben F. Orntoft | Gene expression in bladder tumors |
US6444425B1 (en) * | 1999-04-02 | 2002-09-03 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
EP2270150B2 (en) | 1999-04-09 | 2019-08-07 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
US6949245B1 (en) * | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
CZ20023567A3 (cs) * | 2000-03-29 | 2003-11-12 | Corixa Corporation | Sloučeniny a způsoby pro terapii a diagnostiku karcinomu plic |
US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
US7408041B2 (en) | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
US20040029114A1 (en) * | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
RU2306952C2 (ru) | 2001-01-31 | 2007-09-27 | Байоджен Айдек Инк. | Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами |
AU2002311787A1 (en) | 2001-03-28 | 2002-10-15 | Zycos Inc. | Translational profiling |
WO2002083070A2 (en) * | 2001-04-10 | 2002-10-24 | Corixa Corporation | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
AU2002311909A1 (en) | 2001-05-11 | 2002-11-25 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US20030190640A1 (en) * | 2001-05-31 | 2003-10-09 | Mary Faris | Genes expressed in prostate cancer |
NZ530582A (en) | 2001-07-17 | 2008-06-30 | Res Dev Foundation | Therapeutic agents comprising pro-apoptotic proteins, including granzyme, bax and TNF |
RU2319709C2 (ru) | 2001-07-17 | 2008-03-20 | Рисерч Дивелопмент Фаундейшн | Терапевтические агенты, содержащие проапоптозные белки |
US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
CA2476518A1 (en) * | 2002-02-22 | 2003-09-04 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US20050003390A1 (en) * | 2002-05-17 | 2005-01-06 | Axenovich Sergey A. | Targets for controlling cellular growth and for diagnostic methods |
US20040126379A1 (en) * | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
US20060121029A1 (en) | 2002-08-30 | 2006-06-08 | Hiroshi Shiku | Method and composition for regulating the activity of regulatory t cells |
JP3869352B2 (ja) | 2002-11-12 | 2007-01-17 | 日鉱金属株式会社 | 金属箔の熱量測定方法、表面特性の調整方法、レーザー穴開け方法又は熱量測定装置 |
EP2311870A1 (en) * | 2002-11-26 | 2011-04-20 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
WO2004076682A2 (en) * | 2003-02-26 | 2004-09-10 | Surromed, Inc. | Targets for controlling cellular growth and for diagnostic methods |
EP1629119A2 (en) * | 2003-04-29 | 2006-03-01 | Wyeth | Methods for diagnosing aml and mds by differential gene expression |
EP1639090A4 (en) * | 2003-06-09 | 2008-04-16 | Univ Michigan | COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING CANCER |
WO2005007830A2 (en) * | 2003-07-14 | 2005-01-27 | Mayo Foundation For Medical Education And Research | Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
US20050032113A1 (en) * | 2003-07-17 | 2005-02-10 | Mitsubishi Pharma Corporation | Membrane protein library for proteome analysis and method for preparing same |
WO2005116076A2 (en) | 2004-01-26 | 2005-12-08 | Debiovision Inc. | Neoplasm-specific polypeptides and their uses |
DK1735348T3 (da) | 2004-03-19 | 2012-07-16 | Imclone Llc | Humant anti-epidermalt vækstfaktorreceptorantistof |
DE102004026135A1 (de) | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
WO2006002378A2 (en) * | 2004-06-23 | 2006-01-05 | Avalon Pharmaceuticals | Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods |
JP4957250B2 (ja) | 2005-01-19 | 2012-06-20 | ゼリア新薬工業株式会社 | 抗腫瘍剤 |
PL1846030T3 (pl) * | 2005-01-21 | 2019-05-31 | Genentech Inc | Ustalone dawkowanie przeciwciał her |
CA2598217A1 (en) * | 2005-02-18 | 2006-08-24 | Marsha A. Moses | Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin |
AU2006223374B2 (en) * | 2005-03-11 | 2011-07-21 | Aspira Women’s Health Inc. | Biomarkers for ovarian cancer and endometrial cancer: hepcidin |
JP2006316040A (ja) * | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
US8014957B2 (en) * | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
US7670840B2 (en) | 2006-01-05 | 2010-03-02 | The Ohio State University Research Foundation | Micro-RNA expression abnormalities of pancreatic, endocrine and acinar tumors |
US20100015724A1 (en) * | 2006-08-17 | 2010-01-21 | Peter Hornbeck | Lysine acetylation sites |
WO2008031041A2 (en) * | 2006-09-07 | 2008-03-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanoma gene signature |
WO2008059252A2 (en) | 2006-11-15 | 2008-05-22 | Oxford Biomedica (Uk) Limited | Methods and composition fro t cell receptors which recognize 5t4 antigen |
PT3106873T (pt) | 2007-10-25 | 2019-10-18 | Toray Industries | Método para a deteção de cancro |
JP5663834B2 (ja) | 2008-03-14 | 2015-02-04 | 東ソー株式会社 | 遺伝子組換え抗体の製造方法 |
AR070865A1 (es) | 2008-03-18 | 2010-05-12 | Genentech Inc | Combinaciones de un conjugado anticuerpo- farmaco anti- her2 y agentes quimioterapeuticos y los metodos de uso |
CA2733223C (en) | 2008-08-05 | 2018-02-27 | Toray Industries, Inc. | Pharmaceutical composition comprising anti-caprin-1 antibody for treatment and prevention of cancers |
MX2011001445A (es) | 2008-08-05 | 2011-04-05 | Toray Industries | Metodo para detectar cancer. |
PL2837383T3 (pl) | 2008-08-05 | 2017-07-31 | Toray Industries, Inc. | Środek indukujący odporność |
MX2012001741A (es) | 2009-08-19 | 2012-03-21 | Merck Patent Gmbh | Anticuerpos para la deteccion de complejos de integrina en material incrustado en parafina fijado con formalina (ffpe). |
WO2011035884A1 (en) | 2009-09-22 | 2011-03-31 | Volker Sandig | Process for producing molecules containing specialized glycan structures |
HUE030102T2 (en) | 2010-02-04 | 2017-04-28 | Toray Industries | A pharmaceutical composition comprising anti-caprin-1 antibodies for the treatment and / or prevention of cancer |
DK2532680T3 (da) | 2010-02-04 | 2015-07-20 | Toray Industries | Medicinsk sammensætning til behandling og/eller forebyggelse af cancer |
JP5906739B2 (ja) | 2010-02-04 | 2016-04-20 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
JP5742714B2 (ja) | 2010-02-04 | 2015-07-01 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
DK2532366T3 (da) * | 2010-02-04 | 2017-01-02 | Toray Industries | Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer |
RU2624029C2 (ru) | 2010-02-04 | 2017-06-30 | Торэй Индастриз, Инк. | Лекарственный препарат для лечения и/или профилактики рака |
WO2012005550A2 (ko) | 2010-07-08 | 2012-01-12 | 강원대학교산학협력단 | 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법 |
PL2598531T3 (pl) | 2010-07-26 | 2021-08-30 | Progastrine Et Cancers S.À R.L. | Sposoby i kompozycje do terapii nowotworu wątroby |
HUE033183T2 (en) | 2011-08-04 | 2017-11-28 | Toray Industries | A medicament for treating and / or preventing cancer |
BR112014002616B1 (pt) | 2011-08-04 | 2022-01-18 | Toray Industries, Inc | Método para detectar câncer pancreático |
CA2844038C (en) | 2011-08-04 | 2019-05-07 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
US9175074B2 (en) | 2011-08-04 | 2015-11-03 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
JP6070191B2 (ja) | 2011-08-04 | 2017-02-01 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
US9409993B2 (en) | 2011-08-04 | 2016-08-09 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of pancreatic cancer |
AU2012290952B2 (en) | 2011-08-04 | 2016-05-05 | Toray Industries, Inc. | Cancer treatment and/or prevention drug composition |
WO2013125640A1 (ja) | 2012-02-21 | 2013-08-29 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
DK2818481T3 (da) | 2012-02-21 | 2019-10-14 | Toray Industries | Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer |
MX357505B (es) | 2012-02-21 | 2018-07-12 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
JP6187255B2 (ja) | 2012-02-21 | 2017-08-30 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
KR102052400B1 (ko) | 2012-03-30 | 2019-12-06 | 도레이 카부시키가이샤 | 담낭암의 치료 및/또는 예방용 의약 조성물 |
JP6107654B2 (ja) | 2012-03-30 | 2017-04-05 | 東レ株式会社 | 肝臓癌の治療及び/又は予防用医薬組成物 |
DK2876447T3 (da) | 2012-07-19 | 2020-02-24 | Toray Industries | Fremgangsmåde til detektering af cancer |
WO2014014082A1 (ja) | 2012-07-19 | 2014-01-23 | 東レ株式会社 | 癌の検出方法 |
TR201819812T4 (tr) | 2013-08-09 | 2019-01-21 | Toray Industries | Kanserin Tedavisi Ve/Veya Önlenmesi Amacına Yönelik Farmasötik Bileşim |
-
2009
- 2009-08-05 MX MX2011001445A patent/MX2011001445A/es active IP Right Grant
- 2009-08-05 DK DK14153299.4T patent/DK2733492T3/en active
- 2009-08-05 EP EP09805010.7A patent/EP2325648B1/en active Active
- 2009-08-05 PT PT98050107T patent/PT2325648E/pt unknown
- 2009-08-05 CA CA2732980A patent/CA2732980C/en active Active
- 2009-08-05 PL PL14153299T patent/PL2733492T3/pl unknown
- 2009-08-05 US US13/057,515 patent/US11137401B2/en active Active
- 2009-08-05 RU RU2011108258/15A patent/RU2519089C2/ru active
- 2009-08-05 PL PL09805010T patent/PL2325648T3/pl unknown
- 2009-08-05 CN CN200980139037.XA patent/CN102171570B/zh active Active
- 2009-08-05 WO PCT/JP2009/063883 patent/WO2010016527A1/ja active Application Filing
- 2009-08-05 DK DK09805010.7T patent/DK2325648T3/da active
- 2009-08-05 ES ES14153299T patent/ES2570731T3/es active Active
- 2009-08-05 EP EP14153299.4A patent/EP2733492B1/en active Active
- 2009-08-05 AU AU2009278387A patent/AU2009278387B2/en active Active
- 2009-08-05 JP JP2009546599A patent/JP5644110B2/ja active Active
- 2009-08-05 MX MX2013011525A patent/MX337991B/es unknown
- 2009-08-05 HU HUE14153299A patent/HUE027332T2/en unknown
- 2009-08-05 ES ES09805010.7T patent/ES2471379T3/es active Active
- 2009-08-05 KR KR1020117004614A patent/KR101606779B1/ko active IP Right Grant
- 2009-08-05 KR KR1020167007417A patent/KR20160039295A/ko not_active Application Discontinuation
- 2009-08-05 BR BRPI0911925A patent/BRPI0911925B8/pt active IP Right Grant
-
2014
- 2014-03-24 RU RU2014111182A patent/RU2671497C2/ru active
- 2014-03-31 JP JP2014074263A patent/JP5825386B2/ja active Active
-
2015
- 2015-10-08 AU AU2015238877A patent/AU2015238877B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002540790A (ja) * | 1999-04-02 | 2002-12-03 | コリクサ コーポレイション | 肺癌の治療および診断のための化合物ならびにその使用のための方法 |
JP2003528587A (ja) * | 1999-10-29 | 2003-09-30 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 27個のヒト分泌タンパク質 |
WO2005100998A2 (en) | 2004-04-16 | 2005-10-27 | Europroteome Ag | Membrane markers for use in cancer diagnosis and therapy |
US20080075722A1 (en) | 2006-02-14 | 2008-03-27 | Depinho Ronald A | Compostions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
WO2008088583A2 (en) * | 2006-08-30 | 2008-07-24 | Immunotope, Inc | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
JP2008202320A (ja) | 2007-02-21 | 2008-09-04 | Kajima Corp | シールド機、シールド機とセグメントの間のクリアランス測定方法 |
Non-Patent Citations (10)
Cited By (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11137401B2 (en) | 2008-08-05 | 2021-10-05 | Toray Industries, Inc. | Method for detecting cancer using CAPRIN-1 as a marker |
US9416192B2 (en) | 2008-08-05 | 2016-08-16 | Toray Industries, Inc. | Pharmaceutical composition for treatment and prevention of cancers |
US9982059B2 (en) | 2008-08-05 | 2018-05-29 | Toray Industries, Inc. | Pharmaceutical composition for treatment and prevention of cancers |
EP2532364A1 (en) * | 2010-02-04 | 2012-12-12 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
WO2011096517A1 (ja) * | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
US8709418B2 (en) | 2010-02-04 | 2014-04-29 | Toray Industries, Inc. | Pharmaceutical composition for treating CAPRIN-1 expressing cancer |
EP2532743A1 (en) * | 2010-02-04 | 2012-12-12 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
WO2011096528A1 (ja) * | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2011096533A1 (ja) * | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
US9416191B2 (en) | 2010-02-04 | 2016-08-16 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
WO2011096535A1 (ja) * | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
US9180187B2 (en) | 2010-02-04 | 2015-11-10 | Toray Industries, Inc. | Medicament for treating and/or preventing cancer |
WO2011096519A1 (ja) * | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
EP2532364A4 (en) * | 2010-02-04 | 2013-07-31 | Toray Industries | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF CANCER |
US9115200B2 (en) | 2010-02-04 | 2015-08-25 | Toray Industries, Inc. | Pharmaceutical composition for treating cancer using a monoclonal antibody having immunological reactivity with CAPRIN-1 |
AU2011211699B2 (en) * | 2010-02-04 | 2015-01-22 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
US8937160B2 (en) | 2010-02-04 | 2015-01-20 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
US8911740B2 (en) | 2010-02-04 | 2014-12-16 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
EP2532743A4 (en) * | 2010-02-04 | 2013-09-11 | Toray Industries | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER |
US8828398B2 (en) | 2010-02-04 | 2014-09-09 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
US9175074B2 (en) | 2011-08-04 | 2015-11-03 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
US9273128B2 (en) | 2011-08-04 | 2016-03-01 | Toray Industries, Inc | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
WO2013018894A1 (ja) * | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
CN103718045A (zh) * | 2011-08-04 | 2014-04-09 | 东丽株式会社 | 胰癌的检测方法 |
CN103717738A (zh) * | 2011-08-04 | 2014-04-09 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
KR20140048318A (ko) | 2011-08-04 | 2014-04-23 | 도레이 카부시키가이샤 | 췌장암의 검출 방법 |
KR101984554B1 (ko) | 2011-08-04 | 2019-05-31 | 도레이 카부시키가이샤 | 췌장암의 검출 방법 |
CN103764825A (zh) * | 2011-08-04 | 2014-04-30 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
WO2013018891A1 (ja) * | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
RU2641260C2 (ru) * | 2011-08-04 | 2018-01-16 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и профилактики злокачественной опухоли |
US9796775B2 (en) | 2011-08-04 | 2017-10-24 | Toray Industries, Inc. | Method for detecting pancreatic cancer |
RU2630638C2 (ru) * | 2011-08-04 | 2017-09-11 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака поджелудочной железы |
RU2624040C2 (ru) * | 2011-08-04 | 2017-06-30 | Торэй Индастриз, Инк. | Способ обнаружения рака поджелудочной железы |
EP2740489A4 (en) * | 2011-08-04 | 2015-03-04 | Toray Industries | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF PANCREATIC CARCINOMA |
JPWO2013018883A1 (ja) * | 2011-08-04 | 2015-03-05 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
JPWO2013018891A1 (ja) * | 2011-08-04 | 2015-03-05 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
JPWO2013018892A1 (ja) * | 2011-08-04 | 2015-03-05 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
JPWO2013018889A1 (ja) * | 2011-08-04 | 2015-03-05 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
JPWO2013018894A1 (ja) * | 2011-08-04 | 2015-03-05 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
JPWO2013018885A1 (ja) * | 2011-08-04 | 2015-03-05 | 東レ株式会社 | 膵臓癌の検出方法 |
RU2624049C2 (ru) * | 2011-08-04 | 2017-06-30 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и профилактики злокачественной опухоли |
AU2012290949B2 (en) * | 2011-08-04 | 2017-03-02 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of pancreatic cancer |
RU2611197C2 (ru) * | 2011-08-04 | 2017-02-21 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли |
RU2595400C2 (ru) * | 2011-08-04 | 2016-08-27 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли |
WO2013018883A1 (ja) * | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2013018889A1 (ja) * | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
US9181348B2 (en) | 2011-08-04 | 2015-11-10 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
WO2013018892A1 (ja) * | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
US9180188B2 (en) | 2011-08-04 | 2015-11-10 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
US9181334B2 (en) | 2011-08-04 | 2015-11-10 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
WO2013018885A1 (ja) * | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 膵臓癌の検出方法 |
US9409993B2 (en) | 2011-08-04 | 2016-08-09 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of pancreatic cancer |
US9266958B2 (en) | 2012-02-21 | 2016-02-23 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
RU2639522C2 (ru) * | 2012-02-21 | 2017-12-21 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
WO2013125640A1 (ja) * | 2012-02-21 | 2013-08-29 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
US9273130B2 (en) | 2012-02-21 | 2016-03-01 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
US9260513B2 (en) | 2012-02-21 | 2016-02-16 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
AU2013223143B2 (en) * | 2012-02-21 | 2017-12-21 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
RU2633505C2 (ru) * | 2012-02-21 | 2017-10-12 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
RU2632645C2 (ru) * | 2012-02-21 | 2017-10-06 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
WO2013125654A1 (ja) * | 2012-02-21 | 2013-08-29 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2013125636A1 (ja) * | 2012-02-21 | 2013-08-29 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2013125630A1 (ja) * | 2012-02-21 | 2013-08-29 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
JPWO2013125630A1 (ja) * | 2012-02-21 | 2015-07-30 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
JPWO2013125640A1 (ja) * | 2012-02-21 | 2015-07-30 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
US9573993B2 (en) | 2012-02-21 | 2017-02-21 | Toray Industries, Inc. | Pharmaceutical composition for treatment of cancer comprising an anti-CAPRIN-1 peptide antibody |
JPWO2013125654A1 (ja) * | 2012-02-21 | 2015-07-30 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
JPWO2013125636A1 (ja) * | 2012-02-21 | 2015-07-30 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
AU2013241043B2 (en) * | 2012-03-30 | 2017-11-09 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of gall bladder cancer |
US9428581B2 (en) | 2012-03-30 | 2016-08-30 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of gallbladder cancer |
JPWO2013147176A1 (ja) * | 2012-03-30 | 2015-12-14 | 東レ株式会社 | 胆嚢癌の治療及び/又は予防用医薬組成物 |
AU2013241036B2 (en) * | 2012-03-30 | 2017-07-20 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of liver cancer |
KR102155531B1 (ko) * | 2012-03-30 | 2020-09-15 | 도레이 카부시키가이샤 | 간암의 치료 및/또는 예방용 의약 조성물 |
US9416193B2 (en) | 2012-03-30 | 2016-08-16 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of liver cancer |
WO2013147169A1 (ja) * | 2012-03-30 | 2013-10-03 | 東レ株式会社 | 肝臓癌の治療及び/又は予防用医薬組成物 |
JPWO2013147169A1 (ja) * | 2012-03-30 | 2015-12-14 | 東レ株式会社 | 肝臓癌の治療及び/又は予防用医薬組成物 |
WO2013147176A1 (ja) * | 2012-03-30 | 2013-10-03 | 東レ株式会社 | 胆嚢癌の治療及び/又は予防用医薬組成物 |
KR20150002617A (ko) * | 2012-03-30 | 2015-01-07 | 도레이 카부시키가이샤 | 간암의 치료 및/또는 예방용 의약 조성물 |
EP2876447A4 (en) * | 2012-07-19 | 2016-02-10 | Toray Industries | METHOD OF DETECTING CANCER |
US9753038B2 (en) | 2012-07-19 | 2017-09-05 | Toray Industries, Inc. | Method for detecting cancer via measurement of caprin-1 expression level |
WO2014014086A1 (ja) | 2012-07-19 | 2014-01-23 | 東レ株式会社 | 癌の検出方法 |
JPWO2014014086A1 (ja) * | 2012-07-19 | 2016-07-07 | 東レ株式会社 | 癌の検出方法 |
WO2014014082A1 (ja) | 2012-07-19 | 2014-01-23 | 東レ株式会社 | 癌の検出方法 |
JPWO2014014082A1 (ja) * | 2012-07-19 | 2016-07-07 | 東レ株式会社 | 癌の検出方法 |
US9772332B2 (en) | 2012-07-19 | 2017-09-26 | Toray Industries, Inc. | Method for detecting CAPRIN-1 in a biological sample |
KR102056654B1 (ko) | 2012-07-19 | 2019-12-17 | 도레이 카부시키가이샤 | 암의 검출 방법 |
KR102056137B1 (ko) | 2012-07-19 | 2019-12-16 | 도레이 카부시키가이샤 | 암의 검출 방법 |
US9862774B2 (en) | 2013-08-09 | 2018-01-09 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
RU2611896C1 (ru) * | 2016-03-10 | 2017-03-01 | Федеральное государственное бюджетное учреждение здравоохранения Клиническая больница N 122 имени Л.Г. Соколова Федерального медико-биологического агентства (ФГБУЗ КБ N 122 им. Л.Г. Соколова ФМБА России) | Способ диагностики лейомиомы мочевого пузыря |
CN110573618A (zh) * | 2017-03-30 | 2019-12-13 | 第一三共株式会社 | 抗gpr20抗体 |
RU2818471C2 (ru) * | 2020-04-22 | 2024-05-02 | Общество с ограниченной ответственностью "ДЖЕЙВИС ДИАГНОСТИКС" | Новый раковый антиген для раннего выявления рака, способ его получения, выделения и детекции |
RU2812681C1 (ru) * | 2023-03-27 | 2024-01-31 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ определения предрасположенности к развитию рака щитовидной железы |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5825386B2 (ja) | 癌の検出方法 | |
JP6094220B2 (ja) | 膵臓癌の検出方法 | |
JP5439815B2 (ja) | 癌の検出方法 | |
JP6244912B2 (ja) | 癌の検出方法 | |
JP6244911B2 (ja) | 癌の検出方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980139037.X Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2009546599 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09805010 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2732980 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13057515 Country of ref document: US Ref document number: MX/A/2011/001445 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009278387 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 20117004614 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009805010 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 960/KOLNP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011108258 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2009278387 Country of ref document: AU Date of ref document: 20090805 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: PI0911925 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110204 |